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ABSTRACT 
 
Background: 
Sputum is a non-invasive, economic investigation whereby bronchogenic carcinoma 
can be identified. Manual cytological screening is labour intensive, time-consuming 
and requires a continuous high level of alertness. Automation has recently been 
successfully introduced in gynaecological cytology. Since sputum samples are similar 
to cervical smears, the question arises as to whether they are also suitable for 
automated screening. 
 
Objective: 
This study presented with various objectives:  1) To test automated sputum screening 
using the BD FocalPoint™ Slide Profiler (FP) and compare with manual sputum 
screening.  2) To determine the sensitivity and specificity of sputum in identification of 
bronchogenic carcinoma. 3) To ascertain if any clinical, radiological or bronchoscopy 
findings would be predictors for bronchogenic carcinoma. 4) To determine the 
significance of adequacy. 
 
Method: 
Sputum samples were collected prospectively from patients attending the Division of 
Pulmonology at Tygerberg hospital for a transbronchial fine needle aspiration biopsy 
(TBNA) or a transthoracic fine needle aspiration biopsy (TTNA) for the period from 
2010 to 2012.  A pre-bronchoscopy sputum was collected and submitted for 
processing. Stained slides were put through the FP for automated screening. After 
slides were qualified, sputum slides were put back in the routine screening pool. 
Correlation was done using the TBNA/TTNA result as the standard to evaluate the 
sputum results. 
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Results: 
108 sputum samples were included in this study. Of the 84.3% malignant (n=91) and 
15.7% benign (n=17) cases confirmed with a diagnostic procedure, sputum cytology 
had a sensitivity of 38.5% (35/91 malignant cases), and a specificity of 100% (17/17 
benign cases).  Automated screening had a better sensitivity of 94.3% (33/35 positive 
sputum cases), while manual screening showed a sensitivity of 74.3% (26/35 positive 
sputum cases) when compared to the final sputum result.   
 
Individual parameters with a significant association with positive sputum included the 
presence of an endobronchial tumour, partial airway obstruction / stenosis, round 
mass, spiculated mass (negative association), loss of weight (negative association) 
and squamous cell carcinoma as the histological subtype. Adequacy was not as 
significant as hypothesised since 85.3% of true positive sputum, but also 65.5% of 
false negative sputum, had large numbers of alveolar macrophages present. 
 
Conclusion: 
Sputum cytology remains an important part of the screening programme for 
bronchogenic carcinoma in the public health sector of South Africa.  Results confirm 
that sputum cytology is very specific, and automated screening improves sensitivity.  
Automated screening proved to be more time efficient, resulting in 83.1% reduction 
(p<0.0001) in the screening time spent per case by a cytotechnologist.   
 
Results confirm that the quantity of alveolar macrophages is not directly proprtional to 
pathology representation.  Positive sputum results did however improve with sputum 
adequacy, but had no significant association. 
 
Recommendations from this study include adopting automated sputum screening.     
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ABSTRAK 
 
Agtergrond: 
Die verkryging van ‘n sputummonster is ‘n nie-indringende, ekonomiese ondersoek 
waardeur bronguskarsinoom identifiseer kan word. Nie-geoutomatiseerde sitologiese 
ondersoek is arbeidsintensief, tydrowend en vereis ‘n deurlopende hoë vlak van 
konsentrasie en fokus. Outomatisering is onlangs suksesvol geïmplementeer in 
ginekologiese sitologie-ondersoeke. Aangesien sputummonsters soortgelyk aan 
servikale monsters is, het die vraag ontstaan of sputummonsters ook geskik sou 
wees vir geoutomatiseerde sifting.   
 
Doelwit: 
Hierdie studie het verskeie doelwitte gehad: 1) Om geoutomatiseerde sifting van 
sputummonsters te toets deur gebruik te maak van BD Focal Point ™ Slide Profiler 
(FP), en te vergelyk met nie-geoutomatiseerde sputum sifting.  2) Om die sensitiwiteit 
en spesifisiteit van sputum in die identifikasie van bronguskarsinoom te bepaal. 3) 
Om vas te stel of enige kliniese, radiologiese of brongoskopiese bevindings 
bronguskarsinoom sou kon voorspel. 4) Om die belang van ‘n verteenwoordigende 
monster te bepaal. 
 
Metode: 
‘n Prospektiewe studie van die pasiënte wat die Divisie van Pulmonologie by 
Tygerberg Hospitaal vir transbrongiale nodale aspirasie (TBNA) of ‘n transtorakale 
aspirasie (TTNA) vanaf Julie 2010 tot Mei 2012 bygewoon het,  is gedoen. ‘n Pre-
brongoskopiese sputum is geneem en gestuur vir prosessering.  Die gekleurde 
skuifies is deur die FP gestuur vir geoutomatiseerde ondersoek.  Indien die 
sputumskuifies gekwalifiseer het vir geoutomatiseerde sifting, is hulle in die groep vir 
ondersoek ingesluit. ‘n Korrelasiestudie, om die sputumresultate te evalueer, is 
uitgevoer deur  die TBNA/TTNA bevindings as standaard te gebruik.  
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Resultate: 
Vir hierdie studie is 108 sputummonsters ingesluit.  Vanuit die 84.3% maligne (n=91) 
en 15.7% benigne (n=17) gevalle, bevestig deur ‘n diagnostiese prosedure, het 
sputumsitologie ‘n sensitiwiteit van 38.5% (35/91 maligne gevalle) en ‘n spesifisiteit  
van 100.0% (17/17 benigne gevalle), getoon. Geoutomatiseerde sifting het ‘n beter 
sensitiwiteit met 94.3% (33/35 maligne gevalle), terwyl nie-geoutomatiseerde 
(ondersoek) ‘n sensitiwiteit van 74.3% (26/35 maligne gevalle) wanneer met die finale 
resultaat vergelyk, gevind.  
 
Individuele parameters met ‘n betekenisvolle assosiasie het die teenwoordigheid van 
‘n endobrongiale tumor, gedeeltelike lugwegobstruksie / stenose, ronde massa, ‘n 
spekuleerde massa (negatiewe assosiasie), gewigsverlies (negatiewe assosiasie) en 
plaveiselkarsinoom as die histologiese subtipe, ingesluit.  Geskiktheid van die 
monster was nie so betekenisvol as wat in die hipotese gestel is nie: aangesien 
85.3% van ware positief gediagnoseerde sputummonsters, maar ook 65.5% van die 
vals negatiewe sputummonsters, groot hoeveelhede alveolêre makrofae ingesluit het.  
 
Gevolgtrekking: 
Sputumsitologie bly steeds ‘n belangrike deel van die siftingsprogram vir 
bronguskarsinoom in die openbare gesondheidssektor in Suid-Afrika.  Resultate van 
hierdie studie bevestig dat sputumsitologie baie spesifiek is en dat geoutomatiseerde 
sifting die sensitiwiteit verbeter.  Ge-outomatiseerde sifting het bewys dat dit meer 
tydsbesparend is, met ‘n 83.1% vermindering (p<0.0001) in die siftingstyd wat deur 
een sitotegnoloog per geval bestee word. 
 
Resultate het bevestig dat die hoeveelheid alveolêre makrofae nie direk 
proporsioneel verwant is tot die patologie nie.  Hoe meer verteenwoordigend die 
sputummonster was, hoe groter was die kanse om ‘n akkurate positiewe diagnose te 
maak.  Die assosiasie van die geskiktheid van die sputummonster en die positiewe 
resultate het egter nie ‘n statisties betekenisvolle resultaat getoon nie. 
 
Aanbevelings vir hierdie studie sluit in die aanwending van geoutomatiseerde 
sputumondersoeke. 
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1.  INTRODUCTION 
 
This prospective study was designed to test automated sputum screening on pre-
bronchoscopy sputum in a high risk population, and compare with manual sputum screening.  
The study population comprised of patients referred to the Division of Pulmonology at 
Tygerberg Academic Hospital (TBH) for a transthoracic fine needle aspiration biopsy (TTNA) 
or a transbronchial fine needle aspiration biopsy (TBNA) between July 2010 and June 2012.  
These patients were clinically and radiologically suspected to have intra-thoracic neoplasms.  
 
The automated screening system under investigation, the BD FocalPointtm Slide Profiler (FP), 
is an United States Food and Drug Administration (1) approved automated computerised 
primary screening system for cervical cytology smear preparations (Pap smears).(1, 2)  The 
FP is intended to identify slides with evidence of squamous cell carcinoma or 
adenocarcinoma and their precursor conditions.(3)  Sputum smears and cervical cytology 
smears (Pap smears) share similar characteristics: abnormal cells have similar 
morphological criteria; squamous and glandular malignancies are the most common 
malignant tumours; mucus and contaminants are present in the background; both are 
hypercellular; cytology screening is time-consuming, both requiring a continuous high level of 
alertness; and both are a common screening tool in South Africa.  When carcinoma cells are 
present in sputum, they are often few in number requiring greater diligence from staff to 
screen these cases. For these reasons, and to reduce the false negative rate of sputum 
screening, it was decided to investigate automated sputum screening.   
 
After automated FP screening, the same smears were manually screened by 
cytotechnologists who were blinded to the FP result.  These results were compared to the 
final outcome/diagnosis of the patient determined on FNA or surgical biopsy.  Furthermore, 
this study also explored the correlation between improved quality of sputum with improved 
sensitivity.  Sputum samples were weighed and alveolar macrophages were counted to see if 
an increasing number of macrophages corresponded with increased sensitivity.   
 
A comprehensive list of clinical, radiological and bronchoscopy findings were documented 
and reviewed to determine the strongest predictors for malignancy. 
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2.  LITERATURE REVIEW  
 
Lung cancer has been reported as the most common cancer worldwide for the past several 
decades, accounting for 13% of the total cancer burden in 2008 (all carcinomas, lymphoma, 
leukaemia, myeloma, melanoma and tumours of the brain and nervous system).(4)  South 
Africa is not exempt from this burden, with 1 in 82 males and 1 in 259 females being affected 
by lung cancer during their lifetime.(5)   
 
2.1 Aetiology of lung cancer 
 
Cigarette smoking (tobacco) is by far the dominant risk factor for lung cancer.  Exposure to 
other carcinogens such as asbestos, radon, arsenic, beryllium, bis-choromethyl ether, 
cadmium, chromium, nickel, polycyclic aromatic hydrocarbons, silica, crystalline, vinyl 
chloride and other heavy metals has been shown to increase risk for lung cancer.(6)  
Subsequently, greater incidence of lung cancer has been observed in industries such as 
mining, coal-gas, metal refining and smelting processes, as well as in painting and 
welding.(6)  With the relatively high incidence of employment in mining in South Africa, these 
minor environmental risks may also contribute to our increased burden of lung cancer. 
 
2.2 Clinical features 
 
The majority of patients with bronchogenic carcinoma are symptomatic at presentation.(7)  A 
chronic cough with or without sputum production is the most common symptom. Excessive 
sputum production is an occasional feature of bronchioloalveolar carcinoma / 
adenocarcinoma-in-situ.  Haemoptysis, a common feature in patients with bronchogenic 
carcinoma, frequently prompts patients to seek medical attention.  Localised symptoms are 
caused by invasion of the chest wall or nerves.  This study included various clinical 
parameters that were recorded to determine potential predictors of bronchogenic carcinoma.   
 
Recurrent pneumonia raises the possibility of an obstructive lesion in the airways and should 
prompt further investigation.   
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2.3       Anatomy of respiratory tract 
 
Respiratory cytology is primarily concerned with disease from the lower respiratory tract. This 
includes the trachea, bronchi, bronchioles and alveoli.  Pseudostratified, ciliated columnar 
epithelium, a few goblet, reserve and neuroendocrine cells line the trachea, bronchi and 
bronchioles, while pneumocytes and alveolar macrophages are found in the alveoli. Sputum 
consists predominantly of cells from the upper respiratory tract which consists of squamous 
cells (stratified, non-keratinised squamous epithelium).(8)  The lower respiratory tract is 
usually further subdivided into central (trachea and major bronchi) and peripheral (minor 
bronchi and alveoli) portions.   
 
The lower airways begin at the cricoid cartilage in the trachea, dividing at the carina into the 
left and right main stem bronchi.(9)  The distal trachea and main carina are important sites 
for examination because bronchogenic carcinoma often metastasises to mediastinal lymph 
nodes.(9)  During a TBNA, the mediastinal lymph node station (N) conferring the highest 
tumour staging when found to contain malignant cells is aspirated first, followed by lower 
staged stations and finally the primary tumour (T) (i.e. N3 → N2 → N1 → T).  This approach 
provides vital staging information.  As soon as malignant cells are found, the procedure can 
be concluded as both diagnosis and staging are established.  
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Figure 2.1:  American Thoracic Society and the European Respiratory Society 
(ATS/ERS) lymph node map (10)  
 
2.4 Blood and inflammation 
 
Haemoptysis is a worrying sign of a more serious pulmonary lesion, including Mycobacterium 
tuberculosis (Mtb) or carcinoma.  Macroscopically bloody sputum is strongly associated with 
finding malignant cells in the specimen.(11)  Extremely bloody background may lead to false 
negative results as blood may obscure diagnostic cells or inhibit staining of cells resulting in 
poorly stained smears. 
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Neutrophils normally occur in low numbers (without infection or inflammation) and may be 
increased in cigarette smokers.  Numerous neutrophils usually suggest pneumonia or an 
abscess.(8)  It is important to note that the presence of an inflammatory exudate does not 
exclude malignancy.  The concurrence of pneumonia and malignancy is a potential and 
significant diagnostic dilemma for cytologists (cytopathologist and cytotechnologist). Marked 
inflammatory exudates in the background of malignancy may lead to false negative results. 
Diagnostic cells may be obscured by inflammatory cells or cytologists may decide that the 
sputum merely represents an inflammatory condition. 
 
  
Figure 2.2:  Bloody sputum (a) obscuring malignant cells and result in poor staining.  
Marked inflammatory exudate present (b) partially obscuring diagnostic cells. 
 
2.5  Patient management 
 
Optimum management, diagnosis and care of patients with bronchogenic carcinoma requires 
a ‘’team approach” of dedicated groups of multidisciplinary specialists.  These include 
pathologists, radiologists, pulmonologists, surgeons and oncologists. This study included 
pathology, radiology and bronchoscopy and hypothesised that valuable data would be 
generated following this approach. 
 
a b 
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The Division of Pulmonology at TBH is well established with a good research record.  There 
is an excellent working relationship with the Cytology Unit.  Cytopathologists and 
cytotechnologists/technicians regularly assist with rapid on-site evaluation and diagnosis (12) 
(12) in the outpatient based, bronchoscopy theatre.(13)  Approximately 450 TBNA/TTNA’s 
are performed annually at TBH.  As shown by Diacon et al., ROSE (12) of TBNA is a highly 
useful, accurate and cost-effective addition to routine diagnostic bronchoscopy.(13)  On-site 
discussions with the cytopathologist reduces the incidence of inadequate specimens and 
allow the pulmonologists to focus on specific areas of sampling.(14)  This communication 
can increase cellular yield, and reduce bronchoscopy time when diagnostic cells are found 
quickly.(13) 
   
    
Figure 2.3:  Cytotechnologist (a) and cytopathologist assisting with ROSE in the 
bronchoscopy theatre (b). 
 
a b 
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2.6   Prognosis 
 
The main prognostic factors for bronchogenic carcinoma include the cell type of the tumour, 
general performance status of the patient, any co-morbidities that could affect treatment 
options, the disease staging or extent of the tumour and the treatment modality.(6) The most 
important prognostic factor is determining mediastinal lymph node involvement.(15)  Patients 
with stage I disease who are amenable to surgery have a five-year survival rate of over 60%, 
whereas patients with stage III or IV and are only amenable to palliative treatment have a 
five-year survival rate of less than 10%.(16)  Almost 90% of patients with non-small cell 
bronchogenic carcinoma attending TBH have advanced disease at presentation (stage  IIIB  
or  stage  IV).(17)  These  patients  will  still  require  a  cytological  or  histological  diagnosis  
before  starting  oncology therapy, and the diagnosis is  usually  obtained  with a 
TBNA/TTNA. 
 
2.7   Radiology 
 
Low-dose computed tomography (18) may be used in the evaluation and as a radiological 
screening test for asymptomatic people at risk of lung cancer. Unfortunately this has its own 
side-effects.  The use of CT as a routine method to scan asymptomatic patients is a 
controversial topic.(19)  At this institution, a chest X-ray and staging CT scan of the thorax 
and abdomen is performed on patients suspected of bronchogenic carcinoma to obtain 
information about the extent of disease and plan the diagnostic procedure (i.e. TBNA or 
TTNA).  This provides information on the primary lesion and will reveal possible involvement 
of adjacent structures or metastases required for staging of the carcinoma.(6)  Chest X-rays 
are usually performed at referral clinics or satellite hospitals. 
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Figure 2.4:  Chest X-ray shows a right apical lung tumour (a). Chest CT scan of large, 
peripheral lesion (b) with extension to the pleura, amenable to a TTNA. 
 
Transthoracic ultrasound (US) is used when performing a TTNA on pleural based or 
peripheral lung tumours.(20)  US can visualise parenchymal pathology provided there is 
contact with the pleura.(21) 
 
   
Figure 2.5:  One of the scanning positions for chest US (a). Schematic presentations of 
peripheral lung lesions without (top) and with (bottom) pleural contact (b). Only 
the lesion with pleural contact is visible on ultrasound (15) 
 
a b 
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2.8      Sampling techniques 
 
There is a range of procedures to choose from when patients are investigated for 
bronchogenic carcinoma.  Sputum cytology is an easy, repeatable, non-invasive test and is 
particularly helpful if the patient is not a surgical candidate.  Further invasive staging might be 
avoided in such patients.(15)  At this institution, if metastases are confirmed radiologically 
with a positive sputum, the patient is not a candidate for surgery or curative treatment. If a 
patient has no metastases with positive sputum, the patient will still have to undergo a TBNA 
for staging purposes.   
 
If there is palpable lymph node involvement or easy access to a metastatic site such as a 
pleural effusion, these should be aspirated initially. All other patients will undergo either 
bronchoscopy (fine needle aspiration biopsy, brush, wash or lavage) or a TTNA.  The main 
objective of a TBNA is to diagnose and stage the patient’s tumour at the same time. 
 
Due to the high yield of TBNA/TTNA combined with ROSE, only 81 tissue biopsies were 
performed during 2012 at this institution.  This includes 11 Tru-cut pleural biopsies and 38 
Abrams’ needle pleural biopsies (compared to 453 cytology cases during the same year).  
Schubert et al. suggested that US-guided TTNA should be the first-line investigation in 
patients suspected of a lung malignancy, provided the lesion is accessible.(22)  Overall 
sensitivity was superior in FNA of epithelial lung neoplasms compared to cutting-needle 
biopsy.(22)  Tumours of mediastinal origin, haematopoietic or sarcomatous tumours should 
however undergo FNA and cutting-needle biopsy to harvest tissue, making ancillary 
investigations possible.   
 
Proietti et al. aimed to compare results from cytology and biopsy samples.(23)  Newer 
targeted therapy demands accurate histological subtyping of tumours.  The diagnostic 
concordance of cytology samples with surgical samples was high (P<0.0001).  Definitive 
histological subtype of carcinoma on cytology specimens were accurately reported in 92.8% 
(206/222) of cases.  They concluded that the diagnostic approach to lung cancer does not 
require more invasive procedures. 
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In a study by Sackett et al. they confirmed that it is safe practice to use cytology specimens 
obtained during bronchoscopy as a diagnostic test.(24)  Of the 231 cases in their cohort, 
97.4% had concordant diagnosis between the different pathologists that interpret these 
cases routinely. 
 
Due to the emerging differences in medical treatment between adenocarcinoma and 
squamous cell tumours, accurate histological subtyping of carcinomas has become 
increasingly relevant in developed countries.  Nizzoli et al. investigated the accuracy of FNA 
cytology in non-small cell carcinoma compared to histology.(25)  They reported that when an 
experienced pathologists is reporting on the cases, the results can be used to plan medical 
treatment on, especially when more invasive procedures are not feasible.  
Immunocytochemistry may also be used as an ancillary test to improve diagnostic yield.   
 
In recent years there has been development of prognostic and predictive biomarkers and 
targeted therapeutic agents.  Personalised therapy based on tumour molecular profile can 
improve treatment efficacy.(26)  Most molecular techniques including in situ hybridisation, 
polymerase chain reaction, and transcriptional profiling can be done on FNA/cytology 
specimens.  Hasanovic et al. concluded that FNA has proven to be an invaluable tool for 
diagnostic accuracy of pulmonary carcinomas, while also reliable, adequate and a suitable 
source for molecular testing. 
 
2.8.1. Percutaneous transthoracic fine needle aspiration biopsy (TTNA) 
 
Transthoracic ultrasound (US) is frequently used for the assessment of pleural 
thickening, pleural or peripheral lung tumours as well as chest wall abnormalities.(20)  
US can  visualise parenchymal pathology provided there is contact with the 
pleura.(21)  US increases the diagnostic yield and minimises risk when compared to 
blind procedures.(21)  It is therefore ideal for image-guided chest wall, pleural, 
peripheral pulmonary and mediastinal interventions, including diagnostic 
thoracentesis and biopsy.(20)   
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US-assisted TTNA has the added advantage that it may be performed outside of 
theatre, an  important  practical  consideration  in  patients  with advanced 
disease.(20)  TTNA is generally performed under local anaesthesia with a 22-gauge 
needle.(20) 
 
Diacon et al. demonstrated that US-assisted TTNA with ROSE by a cytopathologist of 
tumours abutting the chest wall has a diagnostic yield of 82%.(27)  US-guided FNA 
had a low complication rate, with pneumothoraces observed in only 1.3% of 
cases.(27)  Studies also showed that US-guided TTNA is significantly superior to 
tissue biopsy in confirming a diagnosis of bronchogenic carcinoma (95% vs. 81%, p = 
<0.05), whereas tissue biopsy is superior in cases of non-carcinomatous tumours and 
benign lesions.(22, 27)  Investigators concluded that tissue biopsy may be reserved 
for cases where cytology is non-contributory and a diagnosis other than bronchogenic 
carcinoma is suspected.(22, 27)  Because TTNA results have been validated 
extensively against histology at this institution, it could be used in this study as one of 
the gold standard tests. 
  
 
Figure 2.6:  Theatre where TTNA is performed, equipped with US. 
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Figure 2.7:  Chest CT (a) and US (b) of peripheral lesions abutting the chest wall 
amenable to TTNA. 
 
2.8.2  Transbronchial (Wang) fine needle aspiration biopsy (TBNA) 
 
Flexible bronchoscopy is an investigation which permits direct visual examination of 
the major airways down to the subsegmental level and thus can verify suspected lung 
cancer in those anatomical areas.  A short, protected and disposable needle attached 
to a flexible plastic catheter is introduced via flexible bronchoscope and can be 
inserted into the lesion of interest under direct vision.(28) Jabbing action allows 
cytological material to be aspirated into the needle while suction is applied to the 
other end with a syringe.(15) The aspirated material is expelled and spread onto 
slides so that ROSE can be performed.  Modern video enabled bronchoscopes have 
a dedicated instrument channel for introduction of TBNA needles under sonographic 
vision. 
 
In bronchogenic carcinoma, TBNA usually establishes the diagnosis and provides 
staging information in a single procedure.(29)  It also facilitates various ancillary 
sampling methods including bronchial brushing and washing for cytology or tissue 
biopsies for histology. Direct vision improves the adequacy and quality of the 
specimens. TBNA enables sampling of mediastinal and hilar lymph nodes providing 
diagnostic and staging information. It is important to plan this procedure according to 
the CT scans thus highlighting the “team approach”.    
 
a b 
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TBNA is an invasive procedure performed only at selected institutions by a 
pulmonologist.  At this institution, yield is improved markedly by the availability of a 
cytopathologist in the bronchoscopy theatre.  This enables immediate evaluation of 
specimens obtained to assess adequacy, assists with guidance of further required 
specimens and often providing an immediate diagnosis.(13)  This is a time-
consuming procedure for a cytopathologist and therefore costly.  
 
 
Figure 2.8:  Bronchoscopy theatre where TBNA is performed, equipped with 
monitors to allow direct vision during bronchoscopy. 
 
         
Figure 2.9:  Flexible bronchoscope (a) and disposable needle (b) attached to a 
plastic catheter which is introduced via the bronchoscope when 
performing a TBNA. 
 
a b 
Stellenbosch University  http://scholar.sun.ac.za
 14 
   
Figure 2.10:  Chest CT scan reveals a central and right sided lung mass which is 
examined before the TBNA to plan the procedure (a).  Distal bronchus 
with fine needle extended from the bronchoscope (b). 
 
2.8.3  Sputum 
 
Significant sputum production indicates the presence of pulmonary disease, therefore 
most patients with bronchogenic carcinoma can spontaneously produce sputum.(8)  
This study only involved patients producing spontaneous sputum.  Although 
Neumann et al. reported improved sensitivity using induced sputum, induction was 
not intended for this study.(30)  This was not employed because we focused on a 
practical way to obtain sputum that could be performed anywhere at any time without 
special equipment or training.  
 
Sputum cytology is an easily obtainable, low-risk, non-invasive, economical 
investigational tool for the assessment of respiratory diseases, including pre-invasive 
and invasive bronchogenic carcinoma.(31, 32)  Sputum samples an extensive area 
and is a relatively sensitive specimen for central tumours or for lesions 
communicating with the airways.(33, 34)  Sputum sampling has no contra-indications 
or complications and can be repeated many times.  Raab et al. concluded that 
sputum cytology, particularly in central lesions, shows significant promise in lowering 
the costs of testing and initial treatment, lowering the lifetime costs of medical care, 
lowering the risk of death from testing and initial treatment, and thus improving life 
expectancy.(33) 
a b 
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Sputum cytology sensitivity is fairly low, with a wide range and little agreement 
between researchers. Schreiber and McCrory (2003) summarised sputum sensitivity 
in published evidence of 16 studies which included more than 28,000 patients.(35)  
These studies were published between 1948 and 1992.  Sputum sensitivity ranged 
from 42% to 97% with an average of 66%.(35)  The variables in these studies 
included method of sputum collection, number of samples obtained, preparation 
technique, tumour size and the experience of the cytopathologist.(35)  The sensitivity 
from pre-bronchoscopy sputum reported ranged from 10% to 74% with an average of 
22%. (35) 
 
Recent studies have shown that sensitivity of sputum specimens have decreased 
over the last decades to less than 50%. (36, 37) It has been suggested that this 
decrease may be due to an increased incidence of more peripheral tumours or that 
clinicians are less motivated to collect good sputum samples. Sputum is only a 
screening test, and not a diagnostic test, while TBNA/TTNA provide fast and accurate 
results.(8)  Bhattacharjee reported in 2010 that malignant cells were present in 33.8% 
of positive cases in their study.(38)  Yield was better in central (72.7%) than 
peripheral lesions (18.2%).(38)   
 
Miura et al. found that patients with positive sputum have a poor 5-year survival rate, 
implying that these patients already have advanced tumours.(39)  Other 
disadvantages of sputum include difficulty in localising lesions, and it is even less 
sensitive for peripheral tumours including adenocarcinoma which has now overtaken 
squamous cell carcinoma as the most common primary lung carcinoma.(17, 33, 34)   
 
In developed countries, the number of sputum samples has fallen dramatically mainly 
due to a combination of the relatively low diagnostic yield of sputum and increased 
use of bronchoscopy.(40)  At this laboratory, 1300 sputum samples for cytology are 
processed annually and 450 TBNA/TTNA’s are attended.   
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South Africa’s medical services are decentralised in rural areas, patients have 
transport difficulties and limited access to hospitals with bronchoscopy units.  
Additionally TBNA/TTNA is expensive.  This makes sputum cytology an important 
potential component of a screening programme for lung carcinoma, especially in 
health care settings with limited resources. We should rather attempt to improve the 
quality and adequacy of sputum obtained from patients, improve cytology screening 
and interpretation. For these reasons automation of sputum screening was attempted 
to ascertain if sputum cytology sensitivity could be improved. 
 
Other situations in which sputum cytology is justifiable include confirming 
unresectable advanced carcinoma, detecting pre-malignant lesions or early 
bronchogenic carcinoma and screening of high-risk patients with occupational 
carcinogen exposure.(41, 42) 
 
2.9   Benign changes 
 
Squamous metaplasia is extremely common. These cells are small and angulated.  
Squamous metaplasia is not considered a pre-malignant condition in itself, but the milieu in 
which carcinoma may arise.(8)  Atypical squamous metaplasia can be associated with lung 
injury, including reaction to inflammation or tumours, and often results in false positive 
diagnosis.(43)  Cells have slightly enlarged nuclei with a high nuclear to cytoplasmic (N/C) 
ratio, the nuclear membrane appears thickened and chromatin hyperchromatic.(8)  
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Figure 2.11:  Reactive (benign) squamous metaplasia (a) with regular nuclear membranes 
and small, regular nucleoli present. Slight nuclear atypia noted in squamous 
metaplastic cells (b) with irregular nuclear membranes and slight 
pleomorphism. 
 
2.10   Pre-invasive lesions 
 
2.10.1  Squamous lesions: 
 
Squamous dysplasia and carcinoma-in-situ are defined as precursor abnormalities for 
squamous cell carcinoma that may occur as single or multifocal lesions.  The 
pathogenesis of squamous cell carcinoma following the steps of hyperplasia, 
metaplasia, dysplasia, carcinoma-in-situ and invasive carcinoma is accepted.(44)  
The diagnosis of dysplasia and carcinoma-in-situ can be difficult, especially when 
differentiating from marked reactive change associated with pneumonia.  
 
Cells from low-grade lesions resemble squamous metaplasia, however dysplasia is 
more pleomorphic in size and shape, with an increased N/C ratio, coarse, 
hyperchromatic chromatin and thick nuclear membranes.(8)  Cells from high-grade 
lesions have small, round to pleomorphic cells with a high N/C ratio, coarse 
hyperchromatic chromatin and irregular nuclear membranes. All these pre-invasive 
lesions lack tumour diathesis.(8)  Tumour diathesis is composed of necrotic debris, 
fibrin, inflammatory cells and altered blood. 
 
a b 
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2.10.2  Glandular lesions: 
 
Atypical adenomatoid hyperplasia is a small (usually less than 5mm in diameter), 
peripheral lesion characterised by proliferation of atypical cells lining the alveoli and 
terminal bronchioles. This has been seen in resection specimens associated with 
adenocarcinoma.(45)  It is important to note that these precursor lesions cannot be 
detected by conventional CT scans, but may be identified at bronchoscopy.  Sputum 
may contain atypical cells that suggest a pre-invasive lesion, leading to improved 
patient management and triage.(46) 
 
Cells from atypical adenomatoid hyperplasia are fairly monotonous with slight atypia, 
dense chromatin, inconspicuous nucleoli and scant cytoplasm, almost resembling 
non-mucinous bronchioloalveolar carcinoma (BAC).(46)  
 
2.11   Bronchogenic carcinoma 
 
Malignant cells have higher N/C ratio’s than benign cells, are more pleomorphic with irregular 
nuclear membranes, abnormal coarse, hyperchromatic, irregularly distributed chromatin.  
Malignant cells in sputum are often small and degenerate, since cells spontaneously 
exfoliate prior to collection time, become trapped in mucus and are coughed out eventually.  
Many bronchogenic carcinomas are mixtures of cell types.(8)  
 
2.11.1  Squamous cell carcinoma 
Squamous cell carcinoma comprises approximately 20% of all bronchogenic 
carcinomas and is strongly associated with a prolonged history of cigarette 
smoking.(47, 48)  At this institution, Nanguzgambo et al. reported that squamous cell 
carcinoma comprised 25.9% of total bronchogenic carcinoma in their series of a total 
of 204 cases.(49)  This was once the most common histological subtype of 
bronchogenic carcinoma, but has been surpassed by adenocarcinoma. It has been 
suggested that the shift has occurred due to increased awareness of smoking as a 
health risk. Promotion of filter cigarettes reduced the average diameter and weight of 
the particles inhaled with cigarette smoke. This favours deposition of carcinogens in 
the peripheral rather than central airways.  (50) 
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The majority of squamous cell carcinomas are located centrally, often causing 
obstructive symptoms such as cough, dyspnoea, haemoptysis, wheezing, stridor or 
pneumonia.(47)  Tumours range considerably in size from small endobronchial 
tumours, to large cavitating lesions that replace an entire lobe.  Metastasis to lymph 
nodes and other organs is very frequent with an unfavourable prognosis and high 
mortality rate.(47)   
 
In sputum, malignant squamous cells typically show differentiated, keratinised cells 
with dense cytoplasm and pyknotic nuclei.(8)  Features indicative of squamous 
differentiation include keratinised cytoplasm, spindled tumour cells, hyperkeratosis 
and pearl formation.(51)  Clues suggesting invasion include high cellularity, diathesis, 
and the presence of frankly malignant-appearing cells, i.e. bizarre shapes, heavy 
keratinisation, irregular chromatin with prominent nucleoli.(8) 
 
2.11.2  Adenocarcinoma 
The incidence of adenocarcinoma has recently increased, and it is now the most 
common primary bronchogenic carcinoma with an average of 38% reported.(17, 48, 
49)  The incidence in some publications has been recorded to be as high as 60%.(47)  
At this institution, Nanguzgambo et al. reported that adenocarcinoma comprised 
55.4% of total bronchogenic carcinoma.(49)  This tumour typically, but not 
exclusively, occurs in the peripheral areas of the lung.(8)  Traditionally, 
adenocarcinoma was mainly divided into bronchogenic adenocarcinoma and BAC.  
However, it has recently been suggested that tumours should be reclassified as 
adenocarcinoma-in-situ (AIS), minimally invasive adenocarcinoma (MIA) and 
adenocarcinoma with a prominent lepidic pattern/component.(12, 52) (Appendix F) 
 
When these tumours are small and peripheral, malignant cells are less readily seen in 
sputum.(51)  Features typical of adenocarcinoma include nucleocytoplasmic polarity, 
multiple or macronucleoli and vacuolated or foamy cytoplasm.(51)  
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2.11.2.1  Adenocarcinoma, conventional type: 
 
Besides the typical features of adenocarcinoma described in 2.11.2, crowded 
three dimensional groups, papillae, cell balls and acini can be seen with 
irregular or lobulated nuclear membranes and relatively vesicular nuclei.(8) 
 
2.11.2.2  Bronchioloalveolar adenocarcinoma: 
 
This tumour refers to various cells of origin including terminal bronchiolar cells 
(mucinous type), Clara cells and type II alveolar pneumocytes (non-mucinous 
type).(8)  Cells are typically well-differentiated and uniform with numerous 
three dimensional aggregates, irregular sheets, minimal nuclear atypia, 
nuclear grooves, intranuclear cytoplasmic invaginations, fine chromatin and 
nucleoli. Cells vary from columnar (mucinous) to cuboidal (non-mucinous); 
additionally, an abundance of mucus in the background may be suggestive of 
this tumour. 
  
2.11.3  Small cell carcinoma 
 
Small cell carcinoma comprises approximately 13% of all bronchogenic 
carcinomas.(48)  At this institution, Nanguzgambo et al. reported that small cell 
carcinoma comprised 14.2% of total bronchogenic carcinoma in their series.(49)  This 
extremely aggressive neuroendocrine tumour commonly presents with distant 
metastases at the time of diagnosis and is associated with a high mortality rate.(47)  
It usually arises in a major bronchus with early hilar lymph node involvement, 
presenting as a peri-hilar mass.(8)  Diagnostic cells are often present in sputum and it 
has been recognised that its central location contributes to this.(8, 11, 30, 53)  
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Malignant cells are often degenerate in sputum with obscured nuclear detail.  Cells 
are typically small (1-2x size of lymphocyte) and hyperchromatic forming loosely 
cohesive strings in mucus strands with nuclear moulding.  Other features include 
scant cytoplasm, inconspicuous nucleoli, round to angulated nuclei with crush 
artefact. The characteristic “salt-and-pepper” chromatin often appears more coarsely 
clumped in sputum due to degeneration of cells.(8) 
 
2.11.4  Large cell carcinoma 
 
This tumour is strongly associated with a history of smoking, and accounts for 
approximately 5% of bronchogenic carcinoma.(47, 48)  At this institution, 
Nanguzgambo reported that large cell carcinoma comprised of only 2.4% of total 
bronchogenic carcinoma.(49)  It tends to occur peripherally and is often attached to 
the pleura or invades adjacent organs.(47)  According to the latest proposed 
classification, large cell carcinoma will be known as “Non-small cell carcinoma, not 
otherwise specified”.(12)  These cells are easily recognised as malignant, but 
typically lack features of specific differentiation. Cells are large and undifferentiated, 
often pleomorphic with markedly irregular nuclear membranes and prominent, 
irregular, multiple nucleoli. Syncytial groups and single cells are a common 
presentation with relatively abundant cytoplasm. Keratinisation and mucin secretion 
are absent. 
 
2.11.5  Adenosquamous carcinoma 
 
These tumours are aggressive and comprise only 0.4-4% of all bronchogenic 
carcinomas.(47)  Minor degrees of dual differentiation are common in primary 
bronchogenic carcinoma.  These tumours have evidence of both keratin formation 
suggestive of squamous differentiation, and mucin secretion suggestive of glandular 
differentiation. Squamous features include dense cytoplasm, distinct cell borders, 
keratin rings and pearls. Glandular features include nucleocytoplasmic polarity, acini 
and mucin.(8)  The newly proposed nomenclature is “Non-small cell carcinoma, with 
squamous cell and adenocarcinoma patterns”.(12)  
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2.12  Screening for bronchogenic carcinoma 
 
Since bronchogenic carcinoma is such a common fatal malignancy (5), all attempts should 
be made to introduce effective screening methods to diagnose it early.  However, thus far 
screening for bronchogenic carcinoma has been a major disappointment as it has not shown 
to significantly reduce mortality.(8)  One of the criteria of a successful screening programme 
is that effective intervention must take place during the pre-symptomatic phase that will alter 
the outcome of the course of the disease. Currently, there are no established screening tests 
for lung cancer available. Of note, this study included a selected population at very high risk 
of lung cancer increasing the probability of a positive sputum compared to randomly 
selected, asymptomatic individuals included in studies of mass screening. 
 
Jett and Midthun reported in 2004 that screening for bronchogenic carcinoma is not currently 
recommended. Unfortunately when patients present with symptomatic disease, the tumour is 
usually advanced. Their study showed that low-dose spiral CT detected smaller tumours 
(average 1.5 cm), compared to chest X-ray (average 3.0 cm). This resulted in 58% to 85% of 
non-small cell carcinomas detected while in stage IA using CT.(54) 
 
Extensive research is being done on biomarker-based screening that could lead to diagnosis 
at a much earlier and more treatable stage. These include molecular markers such as 
heterogeneous nuclear ribonucleoprotein, matrix metalloproteinases, telomerase and 
transforming growth factor β with DNA analysis and fluorescent in-situ hybridisation.(55-60)  
 
2.13  Factors affecting diagnostic sensitivity and reliability of sputum 
 
“Diagnostic sensitivity and reliability of respiratory cytology depends on several factors, 
including time and method of specimen collection, number of samples submitted, tumour cell 
type and differentiation, size and location of the lesion.”(8)  This statement from DeMay was 
used as the basis of one of this study’s objectives to determine if certain clinical, radiological 
or bronchoscopy findings would increase the probability of producing positive sputum. 
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2.13.1  Tumour characteristics 
 
According to Bhattacharjee and Bocking et al., central tumours exfoliate diagnostic 
cells more readily in sputum samples, while the more peripheral the tumour, the fewer 
the number of diagnostic cells present.(34, 38)  Tanaka and Lam reported that there 
is a rough correlation between the size of the tumour and the number of cells it 
sheds, making it more likely to be diagnosed on cytology.(61, 62)  When tumours are 
too large, this can also result in diagnostic difficulties like obstruction of bronchi or 
lesions producing an abundance of necrosis.  The ideal size for optimum exfoliation 
of diagnostic cells is between 3cm and 6cm.(63)   
 
Bocking et al. demonstrated that more advanced tumours are more likely to shed 
diagnostic cells.(34)  According to Berg et al., well differentiated squamous cell 
carcinoma and small cell carcinoma are the most accurately classified primary 
bronchogenic carcinoma, while adenocarcinoma and large cell carcinoma are less 
readily detected in sputum.(53)  They also hypothesised that poorly differentiated 
tumours shed more cells due to decreased intercellular cohesion, and are more 
difficult to classify into a specific tumour type.(8, 63) 
 
2.13.2 Specimen collection 
 
Sputum sensitivity has been shown to improve when more specimens are collected 
for each patient.   Bocking et al. have shown that sensitivity improved from 68% for a 
single sputum specimen, to 78% for two specimens and ultimately to 86% when three 
or more specimens were collected.(34)  This study only collected one sample per 
patient since collection was performed on the same day as the scheduled diagnostic 
procedure.    
 
2.13.3  Adequacy of sputum 
 
Parameters for adequacy include sufficient volume of sputum to allow processing of 2 
cellular slides, cells should be well preserved without obscuring elements and 
numerous alveolar macrophages should be present.(64, 65)   
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Alveolar macrophages indicate that that distal bronchioles and alveoli have been 
sampled.  Their absence indicates that the specimen consists only of saliva and is not 
representative of the lower respiratory tract.  Risse et al. found that sputum with low 
numbers of alveolar macrophages is often found in false negative sputum samples, 
indicating that the mere presence of these macrophages does not accurately 
represent pathology of the lung.(11)  Greenberg stated that “adequacy of sputum 
sample is directly proportional to the number of alveolar macrophages it 
contains.”(66) 
 
Very few current references are available with specific minimum number of 
macrophages prescribed for adequacy.  Johnson and Frable used 6-10 macrophages 
per slide as the standard for adequacy, but without evidence based data.(67)  
Neumann et al. considered sputum specimens to be adequate when at least 50 
alveolar macrophages were present per slide.(30)  The Papanicolaou Society also 
merely stated that numerous alveolar macrophages should be present. (65)  After 
their literature search, they did not find consistent data for a numerical cutpoint for 
macrophages.(65)  The presence of ciliated columnar cells is also not sufficient for 
adequacy, since these cells could have originated from the upper respiratory tract.(8) 
 
Alveolar macrophages are derived from the bone-marrow and are responsible for 
engulfing foreign material and debris in the alveoli.(8)  These macrophages may 
cause diagnostic difficulty with their irregular nuclei, pleomorphism, prominent 
nucleoli and vacuolated cytoplasm, often mimicking carcinoma.(43)  These 
phagocytic cells usually contain particles such as carbon, haemosiderin, lipid or 
mucus.  Carbon particles vary in size, colour and texture, ranging from fine to large, 
black granules often masking the entire cell.  Common sources of carbon include 
cigarette smoking, air pollution and anthracosis.(68)  
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Figure 2.12:  Images of alveolar macrophages. Numerous macrophages present 
with minimal carbon pigment (a), and larger, coarser green to black 
pigment seen in cells (b) which often obscure the nucleus. 
 
2.14  Automated screening 
 
Neethling et al. demonstrated that the FP is sensitive, reproducible and identify scant, single 
lying atypical cells.(69)  A case was identified in their laboratory with only a few abnormal 
cells on it after FP review triaged the case for a full rescreen.  After careful manual rescreen, 
it was identified that there were only 3 abnormal cells present on the entire slide (suggestive 
of a LSIL according to the Bethesda System for reporting cervical smears).  After removing 
the physical dots, the slide was put through the FP slide profiler in 15 different runs.  14 out 
of the 15 runs at least one of the abnormal cells were present in the 15 FOV’s, triaging the 
case for a full rescreen (i.e. 93% sensitivity).  When this case was slipped into a manual 
screeners routine work, she missed all 3 abnormal cells and called the case “within normal 
limits”. 
 
Wong et al. reported that the implementation of the FP significantly decreased their turn-
around-time (27%, p<0.001) for Pap smears and substantially increased their productivity 
(17% improvement) while maintaining diagnostic quality.(70)  Their false negative fraction 
decreased by 36%. 
a b 
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Automated screening was dealt a blow when the outcome of MAVARIC trial was presented 
in 2010 at the International Academy of Cytology Congress.(71)  The long awaited trial was 
the deciding factor if automated screening would be adopted in the United Kingdom (NHS 
Cancer Screening Programme).  Kitchener et al. evaluated the FP as well as the Thinprep® 
Imaging System from Hologic and it was suggested that the introduction of automated 
screening was not justified.  Automated screening was 6.3% less sensitive compared to 
manual screening.  The “no further review” system was very reliable in routine screening 
samples.  Similar cost-effectiveness was determined, but with a 60-80% increase in 
productivity.  Some of their laboratories are now using the instrument as a quality control 
tool. 
 
Colgan et al. concluded in their validation study with a cohort of 10,233 patients that the 
diagnostic performance of the FP is no different to that of manual screening in detecting LSIL 
and worse lesions.(72)  Manual screening identified more ASC-US cases.  They stated that 
they did not experience similar results as the MAVARIC trial i.e. decreased sensitivity using 
the FP. 
 
The RODEO Study Team also compared automated versus manual screening in their 10,165 
cohort.(73)  While using cervical biopsy specimens as the golden standard, they reported no 
statistical significant difference in the results obtained from the 2 methods.  They included 
that the FP safely screened HSIL lesions and was valuable in high volume laboratories.   
 
Finally Sweeney and Wilbur tested the productivity that could be gained by the FP.(74)  
Initially, straight after FP implementation in the laboratory, they reported a merely overall 
average of 2.4% increase in productivity, ranging in individual screeners up to 14.7%.   After 
6 months of using the FP, they reported an overall increase in the laboratories productivity of 
15.4%, ranging in individual screeners up to 26.9%. 
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 2.14.1 History, evolution and FDA approval  
 
 The need to automate Pap smear screening, was already recognised in the 1950’s by 
 Dr. Papanicolaou and his co-workers.(75)  The nature of cervical cytology screening 
 is detecting a few abnormal cells among thousands of normal cells.  Failure of early 
 attempts to automate was contributed to limited computing power and lack of 
 software that could effectively analyse cells.  Substantial pattern recognition 
 capabilities are necessary to distinguish between cancerous and normal cells as well 
 as other types of objects found in the specimens including debris, degenerated cells, 
 cell clusters and contaminants.(76)  With significant information technology advances 
 over the last 15 years, computer screening systems have been more widely accepted 
 and routinely used.(77)   
 
 One of the early instruments that was at the forefront of technological advances in 
 automated screening of conventional smears was the AutoPap® 300 QC System 
 developed by NeoPath, Inc.  Dr Stanley Patten and his team created comprehensive 
 cell charts that listed detailed morphologic criteria for the differentiation of different 
 cell types.(78) (Appendix G)  Engineers would then use this data to produce 
 algorithms used in software programming.   
 
The AutoPap® 300 was approved by the FDA in 1995 as a quality control tool only.   
In 1998, this instrument was again FDA approved, but this time for primary screening 
of conventional slides.(1)  In 1999, NeoPath, Inc. and AutoCyte, Inc. merged to form 
TriPath Imaging, Inc.(77)  In 2001, the AutoPap® 300 got FDA approval to primarily 
screen liquid based cytology slides (SurePathtm  Pap Test slides).  In 2006, 
TriPath Imaging, Inc. agreed to be aquired by Becton Dickinson and Company, and 
this system is currently known as the BD FocalPointtm Slide Profiler (FP).  In 2008, the 
BD FocalPointtm GS Imaging System was approved by the FDA to scan SurePathtm 
Pap Test slides.(1) 
Stellenbosch University  http://scholar.sun.ac.za
 28 
 
2.14.2 The complete BD FocalPointtm System and operation 
 
         
 Figure 2.13:  Stained slides are loaded into the BD FocalPointtm Slide Profiler,  
   screened, and reviewed at the GS Review Station.  
 
The FP is a current, FDA approved, automated computerised primary screening 
system for gynaecological smear preparations.(1, 2)  The instrument classifies slides 
using a high speed video microscope, image interpretation software, and morphology 
computers to image and analyse the complex images on a slide.(3)  A set of 
algorithms is applied to analyse morphologic features.  The instrument is intended to 
detect slides with evidence of squamous cell carcinoma or adenocarcinoma and their 
precursor conditions.(3)  
 
Input hopper 
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The FP is the instrument that actually screens the barcoded slides. It literally 
performs the cytotechnologists’ task by examining the cellular features.  No physical 
dots are made. These are all computerised locations and stored in the database, 
which can be retrieved at the BD FocalPointtm Guided Screening Review Station 
(GS). The FP and the GS does not have to be in the same room since they share a 
network. 
 
 Data is transferred from the FP to the GS.  Computerised locations/dots are now 
available at these remote stations via a network between the various components.  
The slide data is retrieved after scanning the slide barcode and then the automated 
stage on the microscope (also linked to the computer) will automatically take you to 
the 15 fields (FOV’s). 
 
    
 Figure 2.14:  FP (a) is a computerised, automated screening device, networked to a 
  review station (b) where FOV’s are reviewed by a cytotechnologist. 
 
The FP instrument scans the entire slide area under the coverslip, and provides the 
cytotechnologist with 15 designated fields-of-view (FOV’s) with the highest probability 
of containing abnormal cells.  The cytotechnologist interprets these 15 FOV’s at the 
GS Review station, documents a provisional diagnosis and then makes a triage 
decision.  Depending on this diagnosis, slides can  either undergo rapid review if 
benign, or be re-screened if abnormal.  It is of critical importance to note that the 
systems’ diagnostic accuracy relies on the cytotechnologist to make an accurate 
interpretation of the FOV’s.   
a b 
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 Figure 2.15:  An example of a computerised slide created by the FP with designated 
FOV’s to be reviewed by a cytotechnologist. 
 
The FP also provides the user with a Quintile ranking for each case.  Quintiles are 
formed by dividing the print set rankings into 5 equal groups.  Quintile 1 is the 
category of slides with the highest risk, while Quintile 5 is the category of slides with 
the lowest risk for abnormality.  This allows the cytotechnologist to understand the 
risk inherent in each slide.  This ranking is only accurate and of value when a random 
population sample is used (i.e. not all normal or all abnormal cases in a batch), and a 
large batch was processed (preferably 240 slides). This is important for laboratories 
that use the 25% “no further review” function and with low risk populations.  Since 
South Africa does not use the 25% “no further review”, as we are screening a high 
risk population, the quintile ranking was deemed of little importance which might 
create bias.  It was therefore not used in this research project.  In addition, sputum 
samples were processed either with Pap smears batches or alone in small batches. 
Therefore the Quintile ranking would have been of no value. 
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2.14.3 Literature review of automated sputum screening 
  
 The first (and only) report of automated sputum screening was published in 1996 by 
 Hoda et al.(80)  They used the PAPNET® System which was the first automated 
 computerised interactive instrument for conventional Pap smears to be FDA 
 approved.  The study was retrospective and included 122 sputum samples that were 
 randomly selected from their archives. 31 positive sputum samples were included in 
 the study. After PAPNET® scanning and review, 30/31 cases were triaged for full 
 manual review (i.e. 97% sensitivity).  The case that was missed was a small cell 
 carcinoma with only a single group of cells present. These results were encouraging 
 for future use.  The PAPNET® system has since ceased to be marketed in the USA 
 and is no longer commercially available largely due to high costs associated with the 
 system and logistical issues with workflow.(76, 77)  This system required that glass 
 slides be sent to central review sites with scanning stations. 
 
 Neumann et al. suggested the prospect of sputum automation to improve the 
 screening process and diagnostic potential in 2009.(30)  Their article was published 
 just as this study commenced.  
  
 
2.14.4 Instrument validation 
 
A validation study was performed in 2010/11 at this laboratory on the FP.(see 
Appendix I).  9922 conventional cervical cytology slides were evaluated that was 
processed by the FP during a 6-month period.  Only 20 cases were “missed” during 
this period by FP screening (i.e. 8xASC-US, 11xLSIL, 1xHSIL), which equates to 
0.2% false negative/error rate.  Manual screening during the same period averaged 
1.7% false negative/error rate, and therefore the validation was accepted by the 
Quality Assurance division at NHLS. 
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2.14.5 Characteristics shared by Pap smears and sputum: 
 
• Abnormal cells have similar morphological criteria 
• Squamous and glandular malignancies are the most common malignant 
tumours 
• Presence of mucus and contaminants in the background 
• Time-consuming for cytological screening, requiring a continuous high level of 
alertness  
• Hypercellularity 
• High volumes – National Health Laboratory Service (NHLS), TBH processes 
approximately 1300 sputum samples annually  
• Common screening tool 
 
2.14.6 Benefits of automated screening: 
  
Since Pap smears and sputum share characteristics as described in 2.14.5, this study 
was designed to test automated screening of sputum samples to improve sensitivity 
and reduce the false negative rate.  Since carcinoma cells are often sparse, sputum 
screening demands a diligent screener with continuous high level of alertness.  These 
factors contribute to the false negative rate of sputum.  This is what makes automated 
screening well suited for sputum screening. The FP reduces the number of fields to 
be viewed and therefore decrease diligence and prolonged alertness.  The FP is able 
to identify cells whether sparse or abundant as encountered in sputum samples.   
 
DeMay states: “Probably the single most important source of error is loss of 
concentration due to screener fatigue.”(8)  Screening Pap smears and sputum is very 
time consuming to screen and automated screening significantly reduce time spent 
per case.  While a cytotechnologist can manually screen 50 conventional Pap smears 
at this laboratory per day (6.25 slides per hour), he/she can review 130 conventional 
Pap smears per day (16.25 slides per hour) at the GS Review Station.  This 
laboratory has 2 GS Review Stations, and therefore 2 cytotechnologists are able to 
review 260 slides per day instead of screening 100 slides per day, i.e. 160% 
improvement in productivity of Pap smears.   
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Although no published data is available, this laboratory definitely experienced an 
improvement in the cytotechnologist’s internal quality control rate (abnormal cases 
“missed”) while reviewing FP slides compared to manual screening.  Since the FP 
was used optimally, the laboratory’s backlog was diminished and technologists were 
no longer requested to work overtime.  These factors improved the moral of the 
cytotechnologists.  Although the FP reduces the need for cytotechnologists, it cannot 
replace them since they are still vital in the interpretation of data. With the cytology 
laboratories under ever increasing work load pressure and shortage of qualified staff, 
this study, if successful, could be very beneficial.    
 
 
Sputum automation benefits include:  
 Increase productivity and improved turn-around-time (TAT): This will allow 
staff to screen the other non-gynaecological specimens while the FP 
screens the sputum specimens   
 Increased sensitivity and reduce false negative rate: As with Pap smears, 
this instrument is  programmed to identify single lying, sparse atypia as 
demonstrated by Neethling et al.(69, 77) 
 Important extension to the usage of existing FP systems: Since all the 
national cytology laboratories in the NHLS and also some private 
laboratories are currently using the FP system for gynaecological work 
 Improved overall job satisfaction of the cytotechnologist and decreased 
fatigue 
 
 Automated screening would probably also be successful in anal cytology, 
 oesophageal brushings, oral cavity and upper respiratory specimens. 
 
 2.14.7 Limitations to automated screening 
 
Since the cytotechnologist only have 15 fields to view (compared to an entire smear 
in manual screening) before deciding on a diagnosis, cells could be misinterpreted 
resulting in a false negative results.  Kitchener et al. reported on monotony as a factor 
in using automated systems which could lead to decreased concentration and focus 
when reviewing FOV’s. (71)     
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2.14.8 Glandular lesions and automated screening 
 
 Chute et al. reported on the FP’s ability to identify atypical glandular lesions using 
SurePath liquid based cytology slides.(81)  It could be deducted from their study that 
the Quintile ranking was not very reliable for glandular lesions.  These cases were 
distributed throughout all 5 Quintile categories.  At least none of these cases fell in 
the “no further review” category as concluded by them. 
 
 At this laboratory, the “no further review” function is not used due to the high risk 
population that is screened.  As mentioned before, the Quintile ranking is also not 
relied upon, since this often creates bias.   
 
 The question arises: Since adenocarcinoma is the most common type of 
bronchogenic carcinoma diagnosed, could this pose a potential problem?” (49)  
During the past 5 years that the FP has been used at this laboratory, only 1 case of 
endometrial adenocarcinoma had been “missed” on FP screening (i.e. false 
negative), but identified by rapid review.  According to the algorithms designed by 
Patten et al, the FP has been designed to identify adenocarcinoma and its percursor 
lesions. (Appendix G) 
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3.  PILOT STUDY 
 
A pilot study was completed in 2009 to test the prospect of automated sputum screening.  
This was a retrospective study of 84 cases selected from NHLS archives at TBH. These 
cases were received between 2005 and 2008, with an initial diagnosis of “atypia” on 
cytology. The final 35 cases included in the study met the additional criteria of which 
necessitated that both slides processed successfully on the FP.   
 
Only 41.7% of the cases were qualified for study admission after automated screening.  
Possible reasons for this poor result included that slides were old (retrospective study), 
staining had faded and air bubbles had formed.   
 
On follow up, all of these (35) cases were confirmed to be malignant either on subsequent 
tissue biopsy (16 cases), TTNA (12 cases) or TBNA (7 cases).  The results were impressive 
with 33 of the 35 cases (94.3% sensitivity) warranting a full re-screen after FP scanning.  
Please note that squamous metaplasia was also placed into the “full re-screen” category.   
 
Two cases were reported as false negative diagnoses, as they did not present diagnostic 
FOV’s: one adenocarcinoma and one small cell carcinoma.  Specimen adequacy was not 
evaluated.  It was concluded that larger prospective studies were required to confirm 
success.  
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4.  HYPOTHESES AND AIMS 
__________________________________________________________________________ 
 
This study presented with multiple hypotheses, especially due to the collaboration with the 
clinicians at the Division of Pulmonology.  The key purpose was to test automated sputum 
screening and compare with manual sputum screening.  Good sensitivity would be the most 
important consideration. This could relieve some of the workload in understaffed laboratories 
nationally, and possibly worldwide.   
 
4.1.   Hypothesis 1:   
 The sensitivity of automated sputum screening will be comparable to manual 
 sputum screening. 
 
Sputum is one of the most difficult specimens for cytotechnologists to screen since 
abnormal cells are often sparse, specimens are very cellular and sputum often 
contains contamination or inflammatory exudate.  Automated screening using the FP 
has been shown to detect sparse, single lying atypia, which is an imperative feature 
for sputum.(69) 
 
4.2. Hypothesis 2: 
 Certain clinical, radiological and bronchoscopic findings will be able to predict 
 the presence of diagnostic cells representative of bronchogenic carcinoma in 
 sputum samples. 
 
 Studies have shown that tumour size, location and extent play an important role in 
 exfoliation of diagnostic cells into respiratory secretions that appear in sputum. 
 Various parameters were recorded in this cohort to test which factors are associated 
 with positive sputum in patients with bronchogenic carcinoma. 
Stellenbosch University  http://scholar.sun.ac.za
 37 
 
4.3. Hypothesis 3: 
 High numbers of alveolar macrophages in a sputum sample will lead to 
 improved sensitivity for malignancy. 
 
Sputum with an abundance of alveolar macrophages indicates a well representative 
sample from the lower respiratory tract.  The question arises if this optimal sputum 
can accurately represent pathology of the lung.   
 
4.4 Aim 1: 
 To evaluate the usage of the FP in screening sputum samples. 
 
Since automation of Pap smears has been successful in improving turn-around-time, 
reducing backlogs and increasing sensitivity, this could potentially be effective for 
sputum as well. Cellular components and malignant morphologic features of Pap 
smears and sputum are similar. 
 
4.5 Aim 2: 
 To determine the sensitivity and specificity of pre-bronchoscopy sputum 
 samples within a high risk population in South Africa. 
 
Sputum sensitivity reported in the literature has a wide range. This study aimed to 
test sensitivity in patients suspected of bronchogenic carcinoma and attending the 
Division of Pulmonology for a TBNA/TTNA.  This is a population at very high risk for 
bronchogenic carcinoma. 
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5.  METHODOLOGY AND MATERIALS 
__________________________________________________________________________ 
 
5.1   Study settings and patient population 
 
This prospective study was undertaken by collaborators from the National Health Laboratory 
Service (NHLS), Department of Pathology, Division of Anatomical Pathology (including 
Cytopathology) and the Division of Pulmonology, Department Medicine at TBH, in the 
Western Cape, South Africa.  TBH is a 1300-bed teaching and referral hospital in Cape Town 
serving a population of 3.6 million of predominantly mixed ancestry, making it the largest 
hospital in the Western Cape.(82) 
 
Specimen collection occurred over a 2 year period, July 2010 to June 2012.  The sputum 
samples were obtained from a high risk population that included adult patients (older than 18 
years of age) with a clinical suspicion of bronchogenic carcinoma.  All patients able to 
produce spontaneous sputum were invited to participate in the study at the time of arrival to 
the Division of Pulmonology.  Consent was obtained in either English, Afrikaans or Xhosa 
(Appendix D).  In the anteroom (dedicated intake and recovery room) to the theatre, patients 
were instructed to cough deeply and expectorate sputum into a provided container.  
 
 
Figure 5.1:  Dedicated intake and recovery room adjacent to the bronchoscopy 
theatre.  Sputum was collected here before the planned, diagnostic 
procedure. 
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These patients were all scheduled to attend the Division of Pulmonology for a diagnostic 
procedure, either a TBNA or TTNA. TBNA is performed on lesions situated in the central 
airways within reach of a flexible bronchoscope, while a TTNA is performed with US 
guidance on lesions extending to or originating from the pleura.  A few cases were scheduled 
to receive FNA of a palpable lymph node or mass, pleural tap and/or tissue biopsy.     
 
Histology or cytology from conventionally analysed TBNA/TTNA result was used as the 
diagnostic gold standard.  Following extensive validation of cytology from TBNA/TTNA 
against histology in earlier studies at our institution, tissue biopsies are only performed when 
the TBNA/TTNA does not yield diagnostic material upon review by an on-site 
cytopathologist.(22, 27)  Surgical interventions are rare because the diagnostic yield of non-
surgical methods is high and therapeutic resections are seldom indicated as patients present 
with advanced disease. (49) 
 
5.2   Data collection  
 
5.2.1. Patient data (83) 
Unique data collection sheets (Appendix C) were designed on which each patient's 
history and clinical, radiological and bronchoscopic findings were recorded. The 
collected information was obtained by clinicians (co-authors) from the direct interview, 
clinical notes, and any other available supportive documentation.  
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Table 5.1 List of the clinical, radiological and bronchoscopic parameters 
recorded. 
 
Clinical Radiological Bronchoscopic  
Previous tuberculosis Location Endobronchial lesion  
Smoker    Central  Ulcerated lesion  
   Active  Smoker    Peripheral  Exophytic lesion  
   Former  Smoker    Hilar mass  Mucosal thickening 
   Never  Smoked    No clear mass /  nodes only Complete Occlusion  
Cough     Right upper lobe  Stenosis 
   Chronic    Right middle lobe   
   New     Right lower lobe   
Chest pain    Left upper lobe   
Loss of weight (LOW)    Left lower lobe   
Increased dyspnoea     Lingula  
Haemoptysis Size    
Hoarseness     <3cm  
Superior vena cava syndrome     3-7cm  
Pancoast  syndrome    >7cm  
Neurologic symptoms  Mass characteristics  
Paraneoplastic  phenomena     Round  
    Calcified  
    Spiculated  
    Cavitating  
 Atelectasis    
 Pleural  effusion   
 Metastases   
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The interviews were conducted prior to the planned diagnostic procedure.  
Participants were questioned as to symptoms experienced, whether this was a new 
or chronic problem and the estimated duration of the symptom(s).  For the purposes 
of this study, a symptom present for longer than one year was deemed to be chronic.   
 
Prior or on-going history of haemoptysis was documented.  Any patient with a 
subjective experience of worsening dyspnoea (from one class to a higher class in the 
New York Heart Association classification) from their baseline, was included under 
shortness of breath, regardless of their baseline level.(84)  
 
Patients that reported pleuritic chest pain (on coughing or deep inspiration) were 
noted as having chest pain.  In patients with a smoking history, an attempt was made 
to estimate the duration as well as the amount of cigarettes smoked per day with the 
information supplied by the patient. 
 
Patients were questioned about the presence of facial or upper limb oedema and 
examined for venous distension in the neck and distended veins in the upper chest 
and arms or any other features of superior vena cava syndrome.  The presence of a 
tumour compressing the superior cava was subsequently noted on the CT of all the 
patients with these symptoms.  Patients were questioned and examined for any focal 
neurological symptoms or problems with their gait. When available, family members 
were also questioned for confirmation.  In most cases with neurological symptoms, a 
CT scan of the brain had been done prior to the patient’s diagnostic procedure, to 
confirm the suspicion of metastasis/es to the brain.   
 
Participants were asked about any weakness in the muscles of their arms and hands 
and were examined for small muscle wasting.  They were also evaluated for the 
presence of Horner’s syndrome.  If any of these features were found, it was 
correlated with the CT scan to confirm the presence of a Pancoast tumour.  Available 
laboratory findings were briefly reviewed for the presence of hypercalcaemia or 
hyponatraemia, suggestive of syndrome of inappropriate ADH (SIADH) and the 
patient was questioned about recent thrombo-embolic phenomena.  If any of the 
findings were positive with no alternative explanation, the patient was noted as having 
paraneoplastic phenomena. 
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Tumour location 
 If more than one mass was present, the lobe in which the largest mass 
was located was noted as the tumour location 
 If the mass extended across the fissure to involve 2 lobes, both were 
noted as the tumour location 
 Participants were sub classified as having either a central or a peripheral 
mass.  Central: within 2cm of the carina, communicating directly with the 
large airways.  Peripheral: more than 2cm from the carina, clearly 
surrounded by lung parenchyma without communication with the large 
airways 
Tumour size 
 The mass was measured using a digital measuring tool in the axial plane 
on a central electronic radiology review system 
 The maximum diameter was taken and subcategorised as:  <3cm, 3-7cm 
and >7cm   
Specific characteristics of the mass   
 Round: similar diameter in all dimensions with a rounded edge 
 Spiculated:  irregular edged mass 
 
Atelectasis was deemed to be present if there was segmental or lobar collapse with 
volume loss.  The CT scans were reviewed for the presence of pleural effusion of any 
size.  Staging was done based on the Tumour-Node-Metastasis (TNM) 2009 
guidelines.(85) 
 
When bronchoscopy was performed, findings were looked at retrospectively.  The 
description of the mass was based on the findings of the operator who performed the 
bronchoscopy.  If stenosis of the airways was present, the operator subjectively noted 
this as a percentage. 
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5.2.2. Sputum collection 
 
For optimal results of the FP screening, fairly monolayered slides needed to be 
prepared from well preserved, cellular samples.  Sputum samples were collected in 
45ml containers that were pre-filled with 10ml Shandon MUCOLEXXTM.  
MUCOLEXXTM is a mucoliquefying preservative designed for use in the preparation of 
mucoid cytology specimens.(86)  This liquefying process is designed to produce 
slides that contain a high concentration of cells on the slide, with minimal clumping of 
cells.(86)  Microscopically, the cells should not exhibit cellular distortion, destruction 
or affect staining.  Carbowax is routinely used as the sputum fixative at this 
laboratory, but could easily be replaced by MUCOLEXXTM. 
 
Sputum specimens were sent to the laboratory immediately and refrigerated.  
Samples were prepared twice per week by 2 of the collaborators and residual 
material was refrigerated until the study was complete. 
 
During the collection period, a total of 129 sputum samples were collected for 
processing.  In the anteroom to the theatre, the clinician attending to the participating 
patient, allocated a matching study number to the sputum container, unique Cytology 
request form (Appendix B) as well as a collection sheet. The collection sheet with the 
patient identification was stored in the Division of Pulmonology. 
 
   
Figure 5.2:  Images of the data collection sheets, request forms, consent forms and 
sputum containers designed for this study  
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5.3   Inclusion and exclusion criteria 
 
Patients could participate if they were scheduled for a diagnostic procedure and were able to 
produce sputum spontaneously.  The only initial inclusion criterion was successful 
automation.  Patients were included when both slides were qualified after FP screening.   
 
5.4   Safety considerations  
 
This study’s slide preparation was carried out in a Microbiological Safety Cabinet Class II 
(LabAire), in the Cytology Unit’s designated preparation room.  All preparation was 
performed by 2 qualified cytotechnologists.  Safety precautions were strictly adhered to when 
samples were processed.  Protective clothing was worn (laboratory coats and latex gloves) 
while handling the specimens. Careful attention to processing steps was followed to avoid 
cross contamination. The working surfaces were disinfected with 70% ethanol after 
processing each batch.   
 
5.5   Specimen processing 
 
5.5.1 Macroscopic appearance and weight 
 
Upon arrival in the Cytology laboratory, the numbered specimens were allocated a 
laboratory number and registered on the DISA*LAB Laboratory System technologies, 
i.e. computerised database. The macroscopic appearance of the sputum was noted 
and classified as: 
 Watery 
 White 
 Purulent  
 Bloody  
 
The exact weight of the specimens was also documented using an analytical balance 
(Sartorius AY212) to ascertain if sputum quantity would improve the sensitivity.  
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5.5.2 Specimen preparation 
 
The MUCOLEXXTM filled containers were vortexed for approximately 10 seconds and 
blended using a Saccomanno homogeniser.  Sputum samples were homogenised at 
9500 rpm for 5-10 seconds to further liquefy the mucus.  Processing was performed in 
a Microbiological Safety Cabinet Class II. 
 
   
Figure 5.3:  Specimen preparation of sputum collected in Shandon MUCOLEXXTM. 
 
Homogenised specimens were centrifuged in plastic tubes using a swing out head 
centrifuge (Heraeus Multifuge 3s) at 1500rpm for 10 minutes.  The supernatant was 
decanted into the original container and the pellet dislodged to make two thin smears 
using labelled, frosted end glass slides.  2 drops of sediment were placed in the 
centre of one slide, while a second slide was gently placed upside down.  Carefully 
but quickly the two slides were pulled apart.  
 
Spray fixative was not used to fix smears, as the sputum was collected in a fixative, 
and spray fixing usually results in macroscopic clumping of the material. The residual 
pellet was decanted into the original container if more smears were needed. This was 
kept in a laboratory refrigerator at 5°C until the study was complete. 
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After the smears had dried completely, they were stained using a routine 
Papanicolaou stain (Appendix H) in an automated staining instrument (Leica ST 
5020). The smears were manually mounted with glass coverslips using an optimal 
amount of Entellan mounting media (Merck product) to facilitate automated 
screening.  Too little Entellan can yield air bubbles when it dries.  Too much Entellan 
could result in a thick smear or be smeared on top of the coverslip and thus be 
rejected during the FP screening step. 
 
5.5.3 Automated screening 
 
Mounted slides were labelled with barcoded stickers generated by DISA*LAB system. 
This is essential for automated screening, as the instrument links data for each slide 
by this identifier.  Slides were inserted into trays of eight slides each, and placed into 
the input hopper of the FP (instrument serial number 0355).  These slide trays are 
automatically moved to the microscope stage, situated front and centre of the 
instrument.  The instrument checked each slide for physical integrity, read the slide 
barcode label and scanned and analysed the slide at low power and high power 
fields.   
 
Before the first tray and after each tray was processed, a comprehensive system 
integrity assessment of the instrument is performed automatically for quality 
assurance purposes.  This ensures that all data collection and image analysis 
mechanisms are operating within specified limits.(3)  The results of all these tests are 
compared to specific performance limits to validate the processing result for each 
slide in the tray.  Slides can then be classified as qualified (ready to be reviewed) or 
process review (not able to be reviewed). The process review cases were rerun and 
reclassified. When slides remained process reviews, the sputum samples were re-
prepared using the standard preparation procedure as described, and attempted 
automated screening again. 
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5.6  Microscopic examination 
 
5.6.1 Manual microscopy: 
 
Slides were allocated to the Cytology Units’ screening pool. The cytotechnologists 
knew when they were screening study cases, but were blinded from any patient data 
to prevent bias.  Qualified cytotechnologists (screener) were given these cases as 
part of their routine work. Blinded from the FP outcome, screeners applied standard 
criteria to screen these unmarked slides.(8, 47)  Looking at all the fields 
systematically, screeners recorded a diagnosis.  Slides were re-screened by senior 
cytotechnologists (checker) who recorded a final diagnosis (manual dx).  This is 
standard protocol in the cytology laboratory.  The checker was not blinded to the 
screener’s diagnosis, but was blinded to the FP diagnosis. Diagnostic categories are 
as follow:   
 Inadequate 
 Benign 
 Atypical, not otherwise specified (62) 
 Suspicious for malignancy 
 Malignant 
  
For statistical purposes, “Inadequate”, “Benign” and “Atypical, NOS” were considered 
sputum negative.  “Suspicious for malignancy” and “Malignant” categories were 
considered sputum positive.  These categories were compared to the patients finally 
diagnosed with malignancy. If a manual dx of “atypical, NOS” or worse was recorded, 
the result was changed to the Final diagnosis (see 5.6.3), since in practice these 
cases would be reviewed by a cytopathologist. 
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Table 5.2:  Diagnostic categories used for sputum samples in this study 
 
Inadequate Little or no cellular material obtained or material obscured by 
blood, inflammation or poor preservation such that a diagnosis 
cannot be rendered. Also included are sputum samples not 
representative of the lower respiratory tract. (none, or too few 
alveolar macrophages present).(8, 47) 
Benign Negative, no abnormal cells present.  Inflammation or reactive 
changes may be present. Includes benign squamous 
metaplasia. Sputum is adequate. 
Benign squamous metaplasia criteria: cells are round and seen 
in cobble-stone arranged fragments. Cells have a well-defined 
cell border and small to medium sized, smooth, central nuclei.  
N/C ratio fairly low. (8, 47) 
Atypical, NOS 
 
Abnormal cells are present, but of uncertain potential. Adequacy 
is not important. 
Atypical cells are usually sparse with some pleomorphism, 
enlarged nuclei and coarsely granular chromatin. The cytoplasm 
is decreased and may exhibit keratinisation.(8, 47)  
Suspicious for 
Malignancy  
 
Highly atypical cells present, suspicious for malignancy. 
Adequacy is not important. 
Criteria are quantitatively or qualitatively not enough for a 
diagnosis of malignancy.  Cells are pleomorphic with enlarged 
nuclei, slightly irregular nuclear membranes and coarsely 
granular chromatin. The cytoplasm is decreased and may 
exhibit keratinisation.(8, 47) Cells may also appear markedly 
atypical, but with extreme sparse cellularity.   
Malignant 
 
Malignant cells are present.  Adequacy is not important. 
Samples have an abundance of malignant cells with marked 
pleomorphism and a variable N/C ratio.  Nuclear chromatin 
tends to be coarsely granular and hyperchromatic with markedly 
irregular nuclear membranes.  Pearls and keratinisation may be 
present, or balls and other glandular arrangements.  Indian filing 
and moulding may be seen (tumour dependant).(8, 47) 
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5.6.2  FocalPoint interpretation 
 
After manual screening by cytotechnologists, the principal investigator reviewed the 
FP generated FOV’s blinded from the manual diagnosis.  This was not interpreted as 
bias.  The FP diagnosis should reflect the instruments’ capacity to identify cells of 
interest and should not be negatively affected by the quality of the screener to locate 
these cells.   
 
After data transfer from the FP workstation to the server, slides were ready for review 
at the GS Imaging System.  The GS provides the electronic capacity of locating 
diagnostically relevant locations on the slides for screening.(3)  Using the GS 
workstation platform, a computer system networked to an automated microscope 
made triage screening possible.  After reading the barcode, to link data to the slide, 
the microscope automatically positioned the slide at the first relevant location 
identified by the GS system. A user activated footswitch or mouse click moved the 
microscope to the next position until all locations were screened for suspicious cells 
or features.(3)   
 
All 15 fields allocated were carefully screened using the 100x magnification (10x 
objective), and switched to 400x magnification (40x objective) when suspicious cells 
were seen.   A diagnosis was recorded based only on the 15 FOV’s (FP dx) using the 
5 categories (Table 5.2). If a FP dx of “atypical, NOS” or worse was recorded, the 
result was changed to the final diagnosis (see 5.6.3), since in practise these cases 
would be reviewed by a cytopathologist. 
 
5.6.3  Final review 
 
Slides were reviewed by three independent, partially blinded (cytotechnologists 
marked fields to be evaluated, but the diagnosis was concealed) collaborators from 
the Cytology Unit.  Diagnosis was individually recorded, and eventually a consensus 
diagnosis (final dx) was rendered. When two or more cytologists agreed on a 
diagnosis, this was recorded as the final dx. When all three differed in their diagnosis, 
(namely atypical, suspicious and malignant) the middle category (i.e. suspicious) was 
recorded as the final dx.  
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Figure 5.4:  Workflow diagram followed in this study. 
 
5.7   Adequacy 
  
5.7.1  Quantity of alveolar macrophages 
 
A random 10x10mm (100mm2) square was marked off on one of the 2 two slides of 
each case. This was used to count alveolar macrophages using 400 times 
magnification (x40 objective). The total area of the standard coverslip used was 
24x50mm (1200mm2). 
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Figure 5.5:  10x10mm square on slide in which alveolar macrophages were 
counted. 
 
Table 5.3: Bins used in counting alveolar macrophages (factor x12 used) 
 
Counted Alveolar Macrophages 
In 10x10mm area 
Average Alveolar Macrophages 
Per slide 
0             0-11 
1-5         12-60 
6-10         72-120 
11-20                 132-240 
>21           252-600 
 
 
5.7.2 Sputum weight 
 
Sputum were weighed and categorised into one of four groups:  
 0-1g 
 1-3g 
 3-5g 
 >5g 
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5.8.  Ethical approval 
 
Ethical approval was granted (Appendix A) by the Health Research Ethics Committee, 
Faculty of Health Sciences, Stellenbosch University, Cape Town. Ethics Reference number: 
N10/04/135. 
 
Written informed consent for the TBNA/TTNA was obtained from all patients’ prior to the 
bronchoscopy procedure by one of the clinicians. No patient data (name, hospital number 
etc.) were made public, either verbally or in any publication or presentation. The patients’ 
remained anonymous for the purpose of this study.  Patients were free to decline, while their 
management was not affected.  All patients were reviewed at clinico-pathological-radiological 
meetings where individual patient management was discussed.  Patients were only to 
produce sputum if they could, and no additional procedures were involved e.g. sputum 
induction. Patients that agreed to participate in the study were instructed as to what the study 
entailed and consent forms were signed in either English, Afrikaans or Xhosa (Appendix D).   
 
5.9   Statistical analysis 
 
Statistical analysis was performed by Dr. Justin Harvey of Stellenbosch University, Research 
Support. This study was designed as a prospective comparative study.  Univariate analyses 
were performed and p-values calculated using Pearson’s chi-square and Fischer’s two-tailed 
test.  Odds ratios were calculated for the significant factors and Cohen Kappa for the inter-
observer variability.   
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6. RESULTS 
__________________________________________________________________________ 
 
6.1 Final diagnosis of study population 
 
Table 6.1: Final diagnosis of cohort obtained during diagnostic procedure. 
 
 Final diagnosis n=108 % of total cohort 
Malignant  91 84.3 
 Adenocarcinoma, NOS 33 30.6 
 Squamous cell carcinoma 30 27.8 
 Small cell carcinoma 15 13.9 
 Large cell carcinoma 3 2.8 
 Adenosquamous carcinoma 2 1.9 
 Non-small cell carcinoma, NOS 4 3.7 
 Poorly differentiated carcinoma 3 2.8 
 Plasmacytoma 1 0.9 
Benign  17 15.7 
 Mycobacterial infection 4 3.7 
 Inflammation (acute or granulomatous) 4 3.7 
 Benign, NOS 8 7.4 
 Atypical, NOS 1 0.9 
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Figure 6.1: Pie chart illustrating the proportions of the various histological subtypes 
 
6.2 Patient demographics of study population 
 
Table 6.2: Summary of age and gender of the participants in various histological 
subtypes of bronchogenic carcinoma. 
 
 Final Diagnosis Age mean (37-81) Gender (M : F) 
Malignant  59.2 2.4 : 1 
 Adenocarcinoma, NOS 60.0 2.2 : 1 
 Squamous cell carcinoma 59.3 2.3 : 1 
 Small cell carcinoma 60.1 2.0 : 1 
 Large cell carcinoma 60.7 2.0 : 1 
Benign  60.6 1.1 : 1 
 
Results for patients ≤45 years of age:  
 3 patients with a benign diagnosis (aged 40,41,45) 
 1 patient with an adenosquamous carcinoma (aged 37) 
 2 patients with a squamous carcinoma (aged 42,45) 
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Results for patients ≥75 years of age: 
 3 patients with a benign diagnosis (all aged 75) 
 3 squamous cell carcinoma (2 aged 75, 77) 
 1 large cell undifferentiated carcinoma (aged 76) 
 1 small cell carcinoma (aged 81) 
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6.3 Patient data (83) 
 
6.3.1  Clinical characteristics: 
 
Table 6.3: Clinical characteristics of patients in cohort with positive and negative 
sputa. 
 
 
n=90 malignant cases 
   
%  of  
total 
Sputum 
+ 
%  of  
parameter 
Sputum 
- 
%  of  
parameter p-value 
Previous 
tuberculosis 22 24.4 10 45.5 12 54.6 0.616 
Smoker        
   Active smoker 42 46.7 18 42.9 24 57.1 0.520 
   Former smoker 41 45.6 13 31.7 28 68.3 0.278 
   Never smoked 7 7.8 4 57.1 3 42.9 0.424 
Cough (n=82) 78 86.7 31 39.7 47 60.3 0.759 
   Chronic 29 35.4 10 34.5 19 65.5 0.638 
   New  48 58.5 21 43.8 27 56.3 0.463 
Chest pain 51 56.7 22 43.1 29 56.9 0.388 
LOW (n=89) 73 82.0 25 34.3 48 65.8 0.049 
Increased  
dyspnoea (n=88) 60 68.2 25 41.7 35 58.3 0.646 
Haemoptysis 29 32.2 14 48.3 15 51.7 0.250 
Hoarseness (n=89) 23 25.8 9 39.1 14 60.9 1.000 
SVC syndrome 
(n=89) 12 13.5 5 41.7 7 58.3 1.000 
Pancoast syndrome 
(n=89) 5 5.6 3 60.0 2 40.0 0.457 
Neurologic 
symptoms (n=89) 4 4.5 2 50.0 2 50.0 0.644 
Paraneoplastic  
phenomena (n=89) 4 4.5 0 0 4 100 0.151 
 
Loss of weight was significantly more often observed in patients with negative sputum cytology. 
Surprisingly, neither haemoptysis nor coughing was significantly more often seen in patients with 
positive sputum cytology. 
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6.3.2 Radiological characteristics: 
 
 
Table 6.4: Radiological characteristics of patients in cohort. 
 
 
n=90 malignant cases 
   
%  of  
total 
Sputum 
+ 
%  of  
parameter 
Sputum 
- 
%  of  
parameter p-value 
Location        
   Central (n=89) 50 56.2 22 44.0 28 56.0 0.228 
   Peripheral (n=89) 38 42.7 12 31.6 26 68.4 0.228 
   Hilar mass (n=90) 11 12.2 5 45.5 6 54.6 0.745 
   No clear mass /       
   Nodes only (n=90) 6 6.7 3 50.0 3 50.0 0.674 
   Right upper lobe    
   (n=79) 41 45.6 14 34.2 27 65.9 0.495 
   Right middle lobe 
   (n=79) 5 5.6 0 0 5 100 0.151 
   Right lower lobe 
   (n=79) 9 10.0 3 33.3 6 66.7 1.000 
   Left upper lobe 
   (n=79) 22 24.4 10 45.5 12 54.6 0.444 
   Left lower lobe 
   (n=79) 6 6.7 2 33.3 4 66.7 1.000 
   Lingula (n=79) 1 1.1 0 0 1 100 1.000 
Size  (n=78)        
   <3cm 7 9.0 3 42.9 4 57.1 1.000 
   3-7cm 37 47.4 16 43.2 21 56.8 0.352 
   >7cm 34 43.6 10 29.4 24 70.6 0.244 
Mass characteristics  
(n=81)        
   Round 10 12.3 7 70.0 3 30.0 0.039 
   Calcified 3 3.7 2 66.7 1 33.3 0.555 
   Spiculated 68 84.0 22 32.4 46 67.7 0.026 
   Cavitating 7 8.6 2 28.6 5 71.4 0.702 
Atelectasis  (n=90) 44 48.9 17 38.6 27 61.4 1.000 
Pleural effusion  
(n=90) 20 22.2 7 35.0 13 65.0 0.655 
Metastatic  (n=89) 60 67.4 24 40.0 36 60.0 1.000 
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A round mass was significantly more often observed in patients with positive sputum cytology, while a 
spiculated mass was significantly more often observed in patients with negative sputum cytology. 
Surprisingly, neither a central nor a right upper lobe mass was significantly more often observed in 
patients with positive sputum.   
 
6.3.3 Bronchoscopy characteristics: 
 
 
Table 6.5: Findings documented during bronchoscopy of patients in cohort with 
positive and negative sputa. 
 
 
 
n=41 malignant cases 
   
%  of  
total 
Sputum 
+ 
%  of  
parameter 
Sputum 
- 
%  of  
parameter p-value 
Endobronchial lesion  17 41.5 8 47.1 9 52.9 0.045 
Ulcerated lesion  2 4.9 0 0 2 100 0.495 
Exophytic lesion  4 9.8 2 50.0 2 50.0 0.567 
Mucosal thickening 
(n=43) 10 23.3 2 20.0 8 80.0 0.456 
Complete occlusion  8 19.5 3 37.5 5 62.5 0.672 
Stenosis 11 26.8 7 63.6 4 36.4 0.007 
 
Endobronchial lesions and bronchial stenosis were significantly more often observed in patients with 
positive sputum cytology.   
 
6.4 Case selection for FP screening 
 
Initially, the only inclusion criterion was successful automation, i.e. both slides qualified after 
FP screening.  Starting with 129 cases, four cases could not be linked with certainty to the 
respective patients. A further three patients with sputum submitted did not complete 
TBNA/TTNA.  One patient died before a final diagnosis was rendered.  One patient had two 
sputum samples submitted since he had two diagnostic procedures performed on separate 
days.  These sputum samples were excluded from the study. 
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The FP occasionally had difficulty screening these sputum slides since it was not designed 
for sputum samples with its diverse cellular components and contaminants.  During 
automated screening, twelve cases were rejected due to scant cellularity, resulting in 
unsuccessful automation (process reviews).  These sputum samples were also excluded 
from the study. This resulted in a final sample size of 108. 
 
 
 
 
 
 
 
 
 
 
Figure 6.2:  Flow diagram depicting cases that were excluded from the study. 
 
6.5 Manual screening versus automated screening 
 
6.5.1  Duration of manual screening versus automated screening 
 
The standard coverslip size used at this laboratory is 50x24mm2. This equates to 22 
fields (x10 objective) horizontally and 11 fields (10x objective) vertically. Calculated, a 
manual sputum slide will have approximately 242 fields to examine using a 10x 
objective to cover the entire slide. Each case has 2 slides compared to the 15 FOV’s 
generated by the FP that needs to be examined per slide. 
 
The time spent per case (i.e. 2 slides) was recorded, and on average manual 
screening or checking required 19 minutes 14 seconds, while FOV interpretation 
required 3 minutes 15 seconds.  Note that the pre-analytical events (before FOV 
review) were not taken into account e.g. loading, unloading and processing by the FP 
instrument since this does not require cytotechnologist time.  
 
129 sputum samples 
received 
- 4 unlinked - 1 deceased - 1 duplicate - 3 no final diagnosis 
n=120 
- 12 process reviews 
(failed automation) 
 
n=108 sputum samples 
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Table 6.6: Comparison between the duration of manual screening versus FP 
screening.  
 
Efficiency parameter Manual screening FP screening % reduction 
Fields per slide to be reviewed 242 15 93.8 
Time spent per case (mean) 19min14sec 3min15sec 83.1 
p-value <0.001 
 
A significant time difference was established between manual screening and FP screening.  There is 
also no overlap between the minimum time spent during manual screening and maximum of FP 
screening.  
 
 
Figure 6.3: Boxplot using Mann-Whitney test to represent the time spent per sputum 
performing manual screening (screen) versus FOV review (FP). 
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6.5.2 Sensitivity of manual screening versus automated screening 
 
Table 6.7: Comparison between the sensitivity and specificity obtained in sputum 
samples from manual and FP screening. 
 
Screening method True positive sputum samples (n=35) % sensitivity % specificity 
Manual screening 26 74.3 100 
FP screening 33 94.3 97.8 
p-value: 0.803 
 
No statistical significant difference exists between the screening methods. 
 
6.6  Macroscopic examination of sputum samples 
 
6.6.1 Weight 
 
Sputum samples were prepared twice weekly in small batches.  Unused specimen 
containers were not exactly the same weight and slight evaporation of fixative from 
the sealed containers occurred.  This could have resulted in some increased 
variability but not systematic bias.  The average weight of the spontaneous sputum 
samples received was 1.97g with a minimum and maximum weight of 0.0g and 7.22g 
respectively. 
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Table 6.8: Weight of sputum samples recorded in weight bins before processing. 
  
Weight 
bins n=108 
True 
sputum+ 
% in 
category 
True 
sputum- 
% in 
category 
False 
sputum- 
% in 
category 
0-1g 39 6 17.1 7 38.9 26 47.3 
1-3g 45 22 62.9 5 27.8 18 32.7 
3-5g 16 5 14.3 6 33.3 5 9.1 
>5g 8 2 5.7 0 0 6 10.9 
p-value: 0.005 
 
These results seem to indicate a trend with significant differences in results obtained in the first two 
groups (0-1g and 1-3g) between the categories.  Additional testing with more cases in the >5g group 
would be ideal to confirm this trend. 
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Figure 6.4: Boxplot using Kruskal-Wallis test to represent the minimum, maximum 
and median of sputum weight across the results. 
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6.6.2  Macroscopic appearance 
 
Table 6.9: Macroscopic appearance of sputum samples recorded before 
processing. 
 
Macro n=108 True 
sputum+ 
% in 
category 
True 
sputum- 
% in 
category 
False 
sputum- 
% in 
category 
Watery 5 0 0 1 5.6 4 7.3 
White 93 29 82.9 17 94.4 47 85.5 
Purulent 3 1 2.9 0 0 2 3.6 
Bloody 7 5 14.3 0 0 2 3.6 
p-value 0.221 
  
A trend cannot be established since there are too few cases in the watery, purulent and bloody 
categories. 
 
All of the patients with macroscopically bloody sputum samples (100%) had 
bronchogenic carcinoma confirmed on TBNA/TTNA, while 5/7 (71.4%) of these 
bloody sputums had diagnostic cells present. 
 
6.7   Inter observer variability 
 
All abnormal slides were reviewed by 3 independent collaborators (2 cytopathologists and 1 
cytotechnologist) and a consensus diagnosis was rendered.  Cohen’s kappa coefficient was 
calculated on the 35 positive sputum cases which measured the inter-rater agreement.  
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Table 6.10: Kappa coefficient calculations between the 3 cytologists and the consensus 
result. 
 
Rater 1 Rater 2 Cohen Kappa 95% CI 
Consensus dx Cytologist 1 0.452 0.064 – 0.781 
Consensus dx Cytologist 2 0.386 0.062 – 0.688 
Consensus dx Cytologist 3 0.269 0.088 – 0.487 
Cytologist 1 Cytologist 2 0.020 -0.185 – 0.325 
Cytologist 1 Cytologist 3 -0.006 -0.131 – 0.104 
Cytologist 2 Cytologist 3 -0.009 -0.170 – 0.174 
dx=diagnosis; CI=confidence interval 
 
No agreement was established between the three cytologists with the confidence interval including the 
point zero.  At least some agreement was obtained between the consensus diagnosis and the 
individual cytologists. 
 
6.8 Automation performance: 
 
The FP instrument had a high rate of technical errors at the start of the study period, 
resulting in a high process review (23) rate.  The FP image system and plate on the path 
extender were eventually replaced which cleared up the high process review and error rate. 
The PR rate should be kept as low as possible, since these slides have to go back into the 
manual screening pool and does not improve TAT.  This also affected the automation 
performance and success of the sputum samples. 
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Table 6.11: Process review rate for all smears (Pap smears and sputum samples) 
processed during the study period. 
 
Year Process review rate 
2010 15.1% 
2011 20.0% 
2012 9.0% 
 
Table 6.12: Automation performance including process review and failure rate. 
 
FP automation outcome n=120 % 
Initial automation success 85 70.8 
Process review, repeated x1 13 10.8 
Process review, repeated ≥x2 10 8.3 
Failed automation 12 10.0 
 
6.8.1 Reasons for process reviews / incomplete processing included: 
 
Table 6.13: Process review comments after FP screening. 
 
Process Review Status (n=35) %  
Scant cellularity 28.7  
Insufficient reference cells 23.0  
Bubble, 3D or scant specimen 2.1  
Insufficient nuclear-cytoplasmic contrast 14.3  
Specimen/coverslip too thick 14.1  
Dust or dirt on the coverslip 12.0  
Nuclear stain – chromatin blurring 3.1  
Nuclear stain too light/dark 2.7  
Pertaining to “too 
few squamous cells” 
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6.9   Inadequate sputum 
 
Table 6.14:      Clarification of inadequate results. 
 
Inadequacy factor n=108 % 
Total inadequate sputum samples  16 14.8 
    No alveolar macrophages 9 8.3 
    Too few alveolar macrophages 3 2.8 
    >75% cells covered by inflammation 4 3.7 
 
6.10   Inflammatory exudate 
 
Marked inflammatory exudate was commented on when > 50% of cells was covered by 
inflammatory cells.   
 
Table 6.15: Sputum samples with marked inflammatory exudate present 
 
 Inflammatory exudate present % in category 
Sputum of all patients with carcinoma confirmed 36/91 40.0 
All positive sputum cases, suggestive of obstructive 
pneumonia 17/35 48.6 
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6.11   Final diagnostic procedure (method of final result confirmation) 
 
Table 6.16: Summary of diagnostic procedures used to obtain patient diagnosis. 
 
Procedure N=108 % Sputum + % true + Sputum - % false - 
TBNA 45 41.7 11 28.9 34 71.1 
TTNA 46 42.6 19 43.2 27 56.8 
Wash/Brush 7 6.5 1 50.0 6 50.0 
Biopsy 5 4.6 0 0 5 100 
FNA  4 3.7 3 75.0 1 25.0 
Pleural Fluid 1 0.9 1 100 0 0 
p-value < 0.001 
FNA = Fine needle aspirate other than lung 
 
A significant association between the diagnostic procedure and sputum cytology was obtained.  While 
comparing TBNA and TTNA, there is a significant difference between the positive and negative 
sputum results.  When patients had a TTNA as diagnostic procedure, they were more likely to have 
positive sputum cytology.  
 
6.12   Sensitivity and specificity of sputum 
 
Table 6.17: Sensitivity and specificity of sputum results. 
 
Category n=108 % of all sputum Sensitivity Specificity 
True positive 35 32.4   
True negative 17 15.7   
False positive 0 0   
False negative 56 51.9   
Diagnostic accuracy   38.5% 100% 
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6.12.1    Sputum results categorised 
 
Table 6.18: Final sputum diagnosis in the 5 categories and comparison with final 
diagnosis of the patient. 
 
Category n=108 % of cohort % true + True - % False - % 
Inadequate 16 14.8 - 1 6.3 15 93.8 
Benign 43 39.8 - 14 32.6 29 67.4 
Atypical, NOS 14 13.0 - 2 14.3 12 85.7 
Suspicious for 
malignancy 8 7.4 100 - - - - 
Malignant 27 25.0 100 - - - - 
NOS=not otherwise specified                 
                   
All patients with “suspicious for malignancy” sputum cytology were confirmed as 
having bronchogenic carcinoma.      
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6.12.2    Sputum sensitivity in histological subtypes of carcinoma 
 
Table 6.19: Sputum diagnosis compared to the final diagnosis obtained during the 
diagnostic procedure.  An attempt was also made to diagnose the 
exact histological subtype on the sputum. 
  
 Final diagnosis Sputum + % 
Sputum 
- % p-value 
% 
correct 
type 
Malignant  35/91 38.5 56/91 61.5   
 Adenocarcinoma, NOS 10/33 30.3 23/33 69.7 0.351 40.0 
 Squamous cell carcinoma 18/30 60.0 12/30 40.0 < 0.001 83.3 
 Small cell carcinoma 2/15 13.3 13/15 86.7 0.136 100 
 Large cell carcinoma 1/3 33.3 2/3 66.7   
 Adenosquamous carcinoma ½ 50.0 1/2 50.0   
 Non-small cell carcinoma, NOS 2/4 50.0 2/4 50.0   
 Poorly differentiated carcinoma 1/3 33.3 2/3 66.7   
 Plasmacytoma 0/1 0 1/1 100   
Benign All benign cases 0/17 0 17/17 100   
NOS=not otherwise specified 
 
Squamous cell carcinoma was significantly more often observed in patients with positive sputum 
cytology.  Surprisingly, small cell carcinoma, which often has a large central tumour mass, was not 
significantly seen more often in positive sputum cytology but had very poor sensitivity. This might be 
due to the central mass representing metastatic small cell carcinoma originating from a very small 
peripheral primary lesion, whereas squamous cell carcinoma has its primary lesion located centrally.  
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6.13 Predictors of positive sputum (83) 
 
Table 6.20 lists the unadjusted odds ratios for all factors that were found to be associated 
with positive sputum cytology. Data from all 6 factors were available in 39 cases of which 9 
(23.1%) had positive sputum cytology.  
 
Table 6.20: Summarising the predictors of positive sputum cytology.  
 
Parameter p-value OR 95% CI Association 
Bronchoscopy: partial airway obstruction / 
stenosis 0.007 8.9 1.29-61.06 Positive 
CT: round mass 0.039 5.4 1.13-26.06 Positive 
Bronchoscopy: endobronchial tumour 0.045 4.7 0.74-29.83 Positive 
Pathology: squamous cell carcinoma < 0.001 1.9 0.38-9.38 Positive 
CT: spiculated 0.026 0.1 0.03-0.48 Negative 
Clinical: loss of weight 0.049 0.12 0.03-0.45 Negative 
CT= Computed Tomography; OR=odds ratio; CI=confidence interval 
 
6.14  Quantity of alveolar macrophages 
 
This calculation only included 107 sputum samples.  In one of the cases, cells were obscured 
by more than 75% blood and therefore the macrophages could not be counted. 
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Table 6.21: Number of alveolar macrophages present on slides compared to the sputum 
result. 
 
M* per 
1cm2 
M* per 
slide n=107  
True sputum + 
(n=34) 
% in 
cat 
True 
sputum- 
(n=18) 
% in 
cat 
False 
sputum- 
(n=55) 
% in 
cat 
0 0-11 11 1 2.9 0 0 10 18.2 
1-5 12-60 10 2 5.9 2 11.1 6 10.9 
6-10 72-120 1 0 0 1 5.6 0 0 
11-20 132-240 8 2 5.9 3 16.7 3 5.5 
> 21 252-600 77 29 85.3 12 66.7 36 65.5 
p-value: 0.128 
M*= macrophages; “M* per slide” is only an estimate; cat=category 
 
Due to a lack of power, a significant association could not be established between the quantity of 
alveolar macrophages and an improved sputum cytology result.   
 
             
Figure 6.5: Line graph illustrating the percentage of alveolar macrophages present in 
false negative and true positive sputum cases in each bin.  These patients 
had carcinoma confirmed.         
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6.15   Photomicrographs of all the positive cases 
 
Each of the positive sputum samples (c) and its corresponding diagnostic procedure (d) has 
been photographed.   In most cases, radiological images have been included: chest X-ray (a) 
and chest CT scan (b). 
 
Case 1: 56 Male - TBNA of right upper lobe mass in an active smoker with a chronic cough. 
  
  
Figure 6.6:  Large peripheral right upper lung mass on chest X-ray (a) and CT (b).  
Sputum – malignant.  Small aggregates of cells with clumped chromatin, 
thickened nuclear membranes and prominent nucleoli (c).  TBNA - Balls of 
cells with characteristic features of adenocarcinoma in a background of 
reactive lymphocytes (d). 
 
a b 
c d 
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Case 4: 69 Male - TTNA of lower left lobe.  Chronic smoker with severe obstructive 
pulmonary disease.  
  
  
Figure 6.7:   Large mass in the left hemithorax with a broad base of contact with the pleura 
on chest X-ray (a) and CT (b). Sputum - suspicious for malignancy.  Small 
cells with high N/C ratio and multiple nucleoli (c).  TTNA - Adenocarcinoma 
with delicate cytoplasm and multiple nucleoli (d) MGG. 
 
a b 
c d 
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Case 7: 59 Male – TBNA in a patient with weight loss, cough and dyspnoea. 
  
   
Figure 6.8:  Complete collapse of the entire right lung with a central mass and local 
invasion on chest X-ray (a) and CT (b). Sputum – malignant.  Keratinised 
pearls and cells with dense cytoplasm and hyperchromatic nuclei (c).  TBNA - 
Squamous cell carcinoma with necrotic background (d). 
 
a b 
c d 
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Case 12:  49 Male - FNA of a right neck mass in a patient with enlarged cervical lymph node, 
right upper lung mass and Superior Vena Cava syndrome. 
  
  
Figure 6.9:   Large, right upper lobe mass with extensive lymphadenopathy on chest X-ray 
(a) and CT (b). Sputum - suspicious for malignancy.  Large clusters of small, 
moulded, degenerate cells (c).  FNA – Metastatic adenocarcinoma with giant 
cells, abundance of cytoplasm and prominent nucleoli, subclassified as 
pleomorphic carcinoma (d). 
 
a b 
c d 
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Case 13:  67 Male - FNA of a right supraclavicular mass in a patient with a strong smoking 
history, haemoptysis and a suspicious lung lesion on CT.  
  
  
Figure 6.10:  Right middle lobe consolidation with extensive lymphadenopathy on chest X-
ray (a) and CT (b). Sputum – malignant.  Small, degenerate cells forming acini 
(c). FNA - Well differentiated adenocarcinoma with mucin in the background, 
papillary structures and vacuolated cytoplasm; features similar to a BAC (d). 
 
a b 
c d 
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Case 15: 47 Male - TBNA of a patient with marked weight loss, clubbing and a lung mass 
suggestive of malignancy. 
  
  
Figure 6.11:  Large heterogeneously enhancing lesion and associated pleural reaction in 
the posterior segment of the left lower lobe on chest X-ray (a) and CT (b). 
Sputum – malignant.  Sparse, single lying cells with marked nuclear 
irregularities, hyperchromasia and dense cytoplasm (c).  TBNA - Squamous 
cell carcinoma, predominantly non-keratinising (d). 
 
a b 
c d 
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Case 17: 61 Male – TBNA in patient with haemoptysis and reduced sensation of right side of 
the body. 
  
    
Figure 6.12:  Left hilar mass-nodal-complex with infiltration of the left main and upper lobe 
bronchus on chest X-ray (a) and CT (b). Sputum – malignant.  Sparse, single 
lying, high N/C ratio cells with irregular chromatin distribution (c).  TBNA - 
Adenosquamous cell carcinoma (predominant adenocarcinoma). Inlay a 
squamous pearl (d) MGG. CK5 positive in certain cells, BerEP4 positive in 
majority of cells. (images not included)  
 
a b 
c d 
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Case 26: 46 Female - TTNA of right chest mass. 
  
  
Figure 6.13:   Large right hilar mass-nodal-complex extending to the apex of the right lung 
on chest X-ray (a) and CT (b). Sputum – malignant.  Sparse, single cells 
predominantly with marked nuclear irregularities and vacuolated cytoplasm 
(c).  TTNA - Well differentiated adenocarcinoma (d). 
 
a b 
c d 
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Case 27: 70 Male - TTNA of patient with haemoptysis and left lower lobe mass. 
 
 
 
 
  
Figure 6.14:  Sputum – malignant.  Extremely bloody sample.  Degenerate cells have 
hyperchromatic nuclei (a).TTNA - Squamous cell carcinoma with necrosis (b). 
 
a b 
 
No chest X-ray or CT images available 
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Case 29: 50 Male - TTNA of right upper lobe mass.  Patient presented with haemoptysis and 
suspected of Pancoast tumour with thoracic cord compression. 
  
  
Figure 6.15:  Right apical mediastinal mass with extension into the right hilum with a right 
nodal mass complex on chest X-ray (a) and CT (b). Sputum – malignant. 
Marked inflammatory smear with keratinised, spindled cells and nuclear 
irregularities (c). These cells were missed with manual screening. TTNA - 
Squamous cell carcinoma (d). 
 
a b 
c d 
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Case 35: 74 Female - TBNA of patient with weight loss, cough and left upper lobe mass 
suspected of bronchus carcinoma. 
  
  
Figure 6.16:  Circumscribed, lobulated mass in left upper lobe abutting the pleura on chest 
X-ray (a) and CT (b). Sputum – malignant.  Large cells with dense cytoplasm 
and nuclear irregularities (c). These cells were missed with manual screening. 
TBNA - Squamous cell carcinoma, predominantly keratinising type with 
necrosis (d). 
 
a b 
c d 
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Case 37: 49 Male - TTNA of right lower lobe mass. 
  
  
Figure 6.17:  Large central and right lower lobe mass on chest X-ray (a) and CT (b). 
Sputum - malignant. Small aggregates of cells with prominent nucleoli (c).  
TTNA - Squamous cell carcinoma (d). 
 
a b 
c d 
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Case 47: 65 Male - TBNA of subcarinal lymph node in a heavy smoker with weight loss, 
dyspnoea and clubbing.  
  
  
Figure 6.18:   Mediastinal lymphadenoapathy with compression and narrowing of bronchus 
on chest X-ray (a) and CT (b). Sputum - malignant. High N/C ratio malignant 
cells. These cells were missed with manual screening (c). TBNA - 
Adenocarcinoma with vacuolated cytoplasm (d). 
 
a b 
c d 
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Case 48: 50 Female - FNA of soft tissue masses in a patient known with metastatic 
carcinoma. Masses on back, chest wall and breast.  
  
  
Figure 6.19:  Right upper lobe peripheral mass abutting the chest wall on chest CT (a,b) 
Sputum – suspicious for malignancy. Scattered atypical cells with 
hyperchromatic nuclei and dense cytoplasm suggestive of a squamous cell 
carcinoma (c). FNA – Metastatic squamous cell carcinoma (d).  
 
a b 
c d 
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Case 49: 78 Male - TTNA of right upper lobe mass in patient with haemoptysis. 
  
  
Figure 6.20:  Mass causing obstruction of the right upper lobe bronchus with complete 
collapse of the right upper lobe on chest X-ray (a) and CT (b). Sputum - 
malignant. Small balls of cells present with clear, vacuolated cytoplasm and 
eccentric nuclei suggestive of adenocarcinoma (c). TTNA - Poorly 
differentiated carcinoma, likely adenocarcinoma (d). 
 
a b 
c d 
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Case 50: 63 Male - TTNA of right anterior mediastinal mass in ex-smoker with previous 
pulmonary tuberculosis. 
  
  
Figure 6.21:  Large mass involving the right upper lobe and invading the mediastinal 
structures on chest X-ray (a) and CT (b). Sputum - malignant. Clusters of cells 
present with hyperchromatic nuclei and keratinised cytoplasm (c). TTNA - 
Squamous cell carcinoma with hyperchromatic nuclei (d).  
 
a b 
c d 
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Case 56: 59 Male - TTNA of patient with clinically bronchial carcinoma or pulmonary 
tuberculosis. 
  
  
Figure 6.22:  Spiculated mass of the right upper lobe with extension to the anterior thoracic 
lung cage and hilar involvement on chest X-ray (a) and CT (b).  Sputum - 
malignant. Extremely hyperchromatic nuclei with keratinised cytoplasm (c). 
TTNA - Squamous cell carcinoma with abundant necrosis (d). 
 
a b 
c d 
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Case 69: 48 Female - Bronchial brushing of right upper lobe tumour in patient with 
haemoptysis, weight loss, chronic cough and chest pain. 
  
  
Figure 6.23:  Mass in right upper lobe with associative collapse and lymphadenopathy on 
chest X-ray (a) and CT (b).  Sputum - malignant. Sheets of keratinised cells 
with elongated, hyperchromatic nuclei (c). Bronchial brushing - Squamous cell 
carcinoma (d). 
 
a b 
c d 
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Case 78: 51 Male - Retrocarinal FNA of the main bronchus in patient complaining of 
coughing. 
  
  
Figure 6.24:  Small, spiculated lesion in the left upper lobe with surrounding satellite 
nodules on chest X-ray (a), while not seen on CT (b) due to tumour position.  
Sputum – suspicious for malignancy. Extreme scant cellularity.  Cells have 
high N/C ratio’s with multiple nucleoli. These cells were missed with manual 
and automated screening (c). TBNA - Balls of vacuolated cells with 
characteristic features consistent with adenoarcinoma (d). 
 
a b 
c d 
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Case 79: 66 Male - TBNA of left lingula spur in patient with weight loss and haemoptysis. 
  
  
Figure 6.25:  Left hilar, spiculated tumour-nodal complex on chest X-ray (a) and CT (b).  
Sputum - malignant. Small cells scattered with clearing of the chromatin, 
thickened nuclear membranes and prominent nucleoli (c). TBNA - 
Adenocarcinoma (d). 
  
a b 
c d 
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Case 89: 63 Male - TTNA of left lung mass protruding through chest wall in patient with 
weight loss and dyspnoea. 
  
  
Figure 6.26:  Large, extensive, right upper lobe tumour with metastatic spread to the left rib 
cage and left sided hilar lymphadenopathy on chest X-ray (a) and CT (b).  
Sputum - malignant. Large, scattered cells with hyperchromasia and irregular 
nuclear membranes (c). TTNA - Squamous cell carcinoma with extreme 
hyperchromasia (d). 
 
a b 
c d 
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Case 109: 76 Female – TTNA of large, left upper lobe mass in patient known with lobular 
carcinoma of the breast. 
  
  
Figure 6.27:  Left upper lobe mass with infiltration of the chest wall and early rib destruction 
on chest X-ray (a) and CT (b).  Sputum - malignant. Sparse cells present with 
extremely high N/C ratio, chromatin clearing with a thickened, irregular nuclear 
membrane and prominent nucleolus. These cells were missed with manual 
screening (c). TTNA - Large cell undifferentiated carcinoma (d).  
Immunocytochemistry: Progesterone (23) and oestrogen receptors (ER) 
negative (false negative cannot be excluded). PR and ER were strongly 
positive in the core needle breast biopsy. (images not included)  
 
a b 
c d 
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Case 110: 48 Female - TTNA of right upper lobe lesion in patient with chronic cough, chest 
pain and weight loss. 
  
  
Figure 6.28:  Collapse consolidation of the right upper lobe and mediastinal 
lymphadenopathy on chest X-ray (a) and CT (b).  Sputum - suspicious for 
malignancy. Sparse atypical cells present with prominent nucleoli and irregular 
nuclear membranes. These cells were missed with manual screening (c). 
TTNA - Non-small cell carcinoma, suggestive of adenocarcinoma with 
necrosis (d). 
 
a b 
c d 
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Case 111: 68 Male – TTNA in patient with pain, weight loss and rib destruction. 
  
  
Figure 6.29:  Bilateral Pancoast tumours with destruction and erosion of vertebral bodies 
and ribs on chest X-ray (a) and CT (b).  Sputum - suspicious for malignancy. 
Sparse spindled cells present with irregular nuclei (c). TTNA - Squamous cell 
carcinoma with keratinised necrotic debris (d). 
 
a b 
c d 
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Case 112: 77 Male – TTNA of left upper lobe mass. 
  
  
Figure 6.30:  Left upper lobe, peripheral mass abutting the chest wall on chest X-ray (a) and 
CT (b).  Sputum - malignant. Cellular specimen with abundant bizarre, 
keratinised cells and elongated nuclei (c). TTNA - Squamous cell carcinoma 
with abundance of keratinised necrosis (d). 
 
a b 
c d 
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Case 113: 75 Male – TTNA in patient with haemoptysis, wasting and grossly abnormal chest 
X-ray. 
  
  
Figure 6.31:  Complete collapse of the right upper lobe with a mass-nodal-complex in the 
right hilum on chest X-ray (a) and CT (b).  Sputum - malignant. Scattered 
malignant cells covered by a severe inflammatory exudate. Spindled shaped 
cells with marked nuclear irregularities. These cells were missed with manual 
screening (c). TTNA - Squamous cell carcinoma with spindled shapes and a 
necrotic background (d). 
 
a b 
c d 
Stellenbosch University  http://scholar.sun.ac.za
 98 
Case 116: 58 Male – TBNA in patient with haemoptysis, loss of weight and chest pain. 
  
  
Figure 6.32:  Large mass-nodal-complex involving the mediastinum and right hilar area on 
chest X-ray (a) and CT (b).  Sputum - malignant. Scant cellularity of small cells 
in moulded groups with extremely high N/C ratio’s. These cells were missed 
with manual screening (c). TBNA - Small cell carcinoma with characteristic 
smear artefact and cells with high N/C ratio (d). 
a b 
c d 
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Case 121: 55 Female - TTNA of right lung mass in patient presenting with a spontaneous 
pneumothorax. 
  
  
Figure 6.33:  Mass in right lower lobe, occlusion of the bronchus and a mass-nodal-complex 
on the right on chest X-ray (a) and CT (b). Sputum - suspicious for 
malignancy. Sparse spindled cells present with elongated nuclei and dense 
cytoplasm (c). TTNA - Non-small cell carcinoma, squamous cell carcinoma 
with necrosis (d). 
 
a b 
c d 
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Case 125: 51 Male – TBNA in patient complaining of pleuritic-like chest pain. 
  
  
Figure 6.34:  Solid mass lesion in the apex of the right lower lobe, sharing a broad surface 
area with the adjacent pleura on chest X-ray (a) and CT (b). Sputum - 
malignant. Scattered malignant cells with extremely irregular nuclear 
membranes and eccentric nuclei (c). TBNA - Squamous cell carcinoma with 
necrosis (d). 
 
a b 
c d 
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Case 127: 52 Male – TBNA in HIV positive patient with history of pulmonary tuberculosis and 
vertebral body collapse. 
  
  
Figure 6.35:  Left, apical mass adjacent to the mediastinum with infiltration of vertebrae and 
lymphadenopathy on chest X-ray (a) and CT (b). Sputum - malignant. 
Spindled cells with elongated nuclei and keratinised cytoplasm (c). TBNA - 
Squamous cell carcinoma with a keratinising and non-keratinising component 
(d). 
 
a b 
c d 
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Case 128: 66 Female - TBNA in patient with chronic obstructive pulmonary disease and 
possible primary bronchus carcinoma. 
  
  
  
 
Figure 6.36:  Well-defined right upper lobe mass with hilar adenopathy on chest X-ray (a) 
and CT (b).  Sputum - suspicious of malignancy. Small groups of small, 
moulded cells with high N/C ratio. These cells were missed with manual and 
automated screening (c).  TBNA - High N/C ratio cells with moulding 
characteristic of small cell carcinoma (d) MGG. Immunocytochemistry profile 
supports a neuroendocrine carcinoma with Synaptophysin positive (e) and 
MNF positive (f). 
a b 
c d 
e f 
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 Case 129: 58 Male - TTNA of posterior lung tumour in patient with haemoptysis and pleural 
effusion. 
  
  
Figure 6.37:  Mass in left hilum and throughout left upper lobe with associated collapse of 
the left lower lobe on chest X-ray (a) and CT (b).  Sputum -  malignant. Balls 
of cells present with vacuolated cytoplasm suggestive of adenocarcinoma (c). 
TTNA - Non-small cell carcinoma, favour a squamous cell carcinoma or 
adenosquamous carcinoma (d). 
 
a b 
c d 
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Case 133: 56 Female - 200ml brown coloured pleural fluid received for processing. 
  
  
Figure 6.38:  Involved mediastinal lymph nodes with large right sided pleural effusion on 
chest X-ray (a) and CT (b).  Sputum - malignant. Cells seen in balls with 
abundant, clear, vacuolated cytoplasm (c). Pleural effusion - Metastatic 
adenocarcinoma (d). 
 
a b 
c d 
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Case135: 42 Female - TTNA of a mass in the right lung extending to the pleura and massive 
pleural effusion.  
  
  
Figure 6.39:  Right lung collapse with ipsilateral pulmonary nodules on chest X-ray (a) and 
CT (b).  Sputum - malignant. Cells had prominent nucleoli with marked 
clumping and clearing of chromatin. Cytoplasm appeared dense (c). TTNA - 
Squamous cell carcinoma, non-keratinising (d). 
 
a b 
c d 
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Case 138: 56 Female – TTNA in patient known with bronchogenic carcinoma and in need of 
new staging CT. 
  
  
   
Figure 6.40:  Large left perihilar mass with multiple pleural based and pulmonary nodules 
and lymphadenopathy on chest X-ray (a) and CT (b).  Sputum - malignant. 
Small, poorly differentiated cells with high N/C ratio’s (c). TTNA - 
Adenocarcinoma with neuroendocrine differentiation (d) confirmed with 
immunocytochemistry: strong BerEP4 positivity (e) and Synaptophysin 
positivity (f) while CK5 was negative (g).  
a b 
c d 
e f g 
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7.  DISCUSSION 
 
7.1 Patient demographics of study population  
 
This prospective, laboratory-based comparative study was conducted on pre-bronchoscopy 
sputum submitted from adult patients attending the Division of Pulmonology at TBH for 
suspected bronchogenic carcinoma.  Sputum from a total of 108 patients was included. The 
average age of the 91 patients with confirmed bronchogenic carcinoma was 59.2 (range 37 - 
81), compared to the 17 patients with benign disease aged 60.6 (range 40 - 78).  Gender 
distribution in patients with bronchogenic carcinoma was 29.7% females (n=27), and 70.3% 
males (n=64), compared to benign disease with 47.1% females (n=8), and 52.9% males 
(n=9).   
 
7.2 Patient data (83) 
 
The patient data included clinical, radiological and bronchoscopic characteristics.  
 
7.2.1 Clinical characteristics 
 
Among the 91 patients with confirmed bronchogenic carcinoma, the most frequently 
observed clinical symptoms included cough (n=78; 39.7% positive sputum) and loss 
of weight (n=73; 34.3% positive sputum). The presence of weight loss was negatively 
associated with positive sputum cytology (p=0.049).  Only 25 patients with weight loss 
had positive sputum, while in total 82.0% of patients (n=73) with weight loss had 
carcinoma confirmed.  24.4% of the patients reported a history of tuberculosis (n=22; 
45.5% positive sputum) and almost all were smokers or ex-smokers (n=83; 34.4% 
positive sputum) with a mean of 33 pack-years.  7 Patients had bronchogenic 
carcinoma confirmed but denied to have smoked before (57.1% positive sputum).   
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None of the symptoms above were associated with positive sputum cytology, neither 
were general tumour symptoms such as shortness of breath (n=60; 41.7% positive 
sputum) and various paraneoplastic syndromes (n=4; 0% positive sputum). 
Surprisingly, none of the clinical manifestations generally associated with a central 
tumour location such as hoarseness (n=23; 39.1% positive sputum), haemoptysis 
(n=29; 48.3% positive sputum) or superior vena cava syndrome (n=12; 41.7% 
positive sputum) predicted the sputum cytology outcome.  Neither of the symptoms 
generally associated with a peripheral tumour such as chest pain (n=51; 43.1% 
positive sputum) or Pancoast syndrome (n=5; 60.0% positive sputum) predicted a 
positive sputum result.  
 
While 14 patients reported haemoptysis, only 7 of the sputum samples were 
macroscopically blood stained. All these macroscopically blood stained sputum had 
bronchogenic carcinoma confirmed, while 5 of these patients (71.4%) had positive 
sputum cytology. This data correlates with results from Risse et al. reporting a strong 
association between macroscopic bloody sputum and the presence of malignant cells 
in sputum.(11) 
 
 7.2.2 Radiological characteristics 
  
From the literature review, expected radiological results associated with positive 
sputum included central tumours and tumours communicating with the airways. (33, 
34, 38)  Of the 50 patients with central malignant lesions, 44% had positive sputum 
(n=22) compared to the 38 patients with peripheral malignant lesions of which 31.6% 
had positive sputum (n=12). These results correlate with Neumann et al. that reported 
more frequent positive sputum in central lesions, but with relatively small differences 
compared to peripheral lesions. (30)  
 
The most frequent site for malignant tumours were right upper lobe (n=41; 34.2% 
positive sputum) masses.  Surprisingly, left upper lobe tumours had the highest 
proportion of positive sputum (n=22; 45.5% positive sputum). We anticipated that 
right upper lobe tumours would be more likely to exfoliate diagnostic cells with its 
proximity to the central airways.  None of these specified sites, however, was 
significantly associated with positive sputum. 
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Tumour size characteristics showed no significant association with positive sputum.  
Many of the tumours were more than 7cm in diameter (N=34) and these showed less 
positive sputum results (29.4%) compared to the smaller tumours (43.2% positive 
sputum).  This data correlates with results discussed by Pilotti et al.  They stated that 
when tumours are too large, they may obstruct bronchi or produce an abundance of 
necrosis.(63) 
 
Spiculated tumours were negatively associated with positive sputum.  Only 32.4% of 
these patients had positive sputum (n=22), while in total 84.0% of patients with 
spiculated lesions had carcinoma confirmed.  The presence of a round mass (n=10; 
70.0% positive sputum) was positively associated with sputum cytology.  
 
Neither associated pleural effusion (n=20; 35.0% positive sputum) nor metastasis 
(n=60; 40.0% positive sputum) showed increased sputum sensitivity.   
 
7.2.3 Bronchoscopic characteristics 
 
Bronchoscopy related findings significantly associated with positive sputum were the 
presence of an endobronchial tumour (n=17; 47.1% positive sputum) and airway 
obstruction or stenosis (n=11; 63.6% positive sputum).  Only a few of the patients had 
exophytic (n=4; 50.0% positive sputum) or ulcerated lesions (n=2; 0% positive 
sputum) and showed no significant association with positive sputum as expected.  
This can also be attributed to the small sample with these tumour characteristics. 
 
7.3 Comparing manual screening to automated screening 
 
Manual screening was performed by various cytotechnologists (screener: 0-15 years 
experience; checker: ≥10 years experience) employed at the NHLS Cytology Unit situated in 
TBH.  They were blinded from all patient data and automated screening results.  Automated 
screening was performed by the FP, and the FOV’s interpreted by one cytotechnologist 
(principal investigator with 10 years experience). She was also blinded to all the patient data 
and manual screening result.   
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7.3.1 Efficiency of manual compared to automated screening 
 
Automated screening was significantly more time efficient (p<0.001) resulting in 
improved TAT. There was a 93.8% reduction in fields to be reviewed, resulting in an 
overall 83.1% reduction in the screening time spent per case by a cytotechnologist.  
The minimum time spent on manual screening and the maximum time spent of FP 
screening did not even overlap. 
 
 7.3.2 Sensitivity of manual compared to automated screening 
 
 The automated screening results (94.3%) were more sensitive than manual screening 
 (74.3%).  This is surprising and encouraging.  No statistical significant difference 
 exists between the two screening methods. 
 
The FP has been designed for cervical cytology, and although the cells found in 
sputum and Pap smears are rather similar, there are still some differences.  These 
include the presence of: 
 alveolar macrophages usually with an abundance of carbon ingested 
mimicking atypia / malignancy  
 more food particles including vegetable cells  
 malignant cells usually smaller due to degeneration as a result of prior, natural 
exfoliation   
 abnormal cells usually more sparse than on Pap smears. 
 
Manual sputum screening is extremely difficult and requires concentration, 
thoroughness and is extremely time consuming.  For these reasons automated 
screening is well suited to reduce the fields to be looked at (as described in 7.3.1), 
allowing screeners to spend more time on potential abnormal fields. 
 
This study obtained a good sensitivity with automated screening.  This allowed us to 
dismiss pessimistic predictions that the presence of alveolar macrophages with 
abundant carbon pigment could interfere with automated screening.  Macrophages 
may mimic enlarged, hyperchromatic, malignant nuclei and it was contemplated that 
these cells could be misinterpreted by the FP.  
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There are no data available at this laboratory for the sensitivity of routine sputum 
cytology.  There is no reference point and specimens are currently not correlated with 
the various cytology tests or pathology.  NHLS at TBH drains a large area, and not all 
these patients are referred to TBH for a diagnostic procedure. 
 
7.3.3 Specificity of automated screening 
 
As discussed in the literature review, the FP acts as a triage mechanism.  A 
provisional diagnosis is recorded by the cytotechnologist who will determine if slides 
will be rapid reviewed if benign, or re-screened if abnormal.  Only 1 case (from 46 
triaged for re-screen) had a provisional diagnosis of “atypical, NOS” which was 
eventually reported as “benign” due to tuberculosis. This resulted in a specificity of 
97.8% for FP screening. 
 
7.4 Macroscopic examination of sputum samples 
 
Before preparation, sputum samples were weighed and the macroscopic appearance was 
noted. 
 
7.4.1 Weight of sputum samples 
 
Most of the positive sputum samples obtained, weighed between 1 and 3 grams 
(n=45; 48.9% positive sputum).  The positive results did not show an increase 
proportional to the sputum weight increase.  Most of the false negative sputum 
samples weighed less than 1 gram (n=26; 66.7% negative sputum).   
 
 Results seem to indicate a trend with significant differences (p=0.005) in results 
 obtained in the first two groups (0-1g and 1-3g) between the categories.  Additional 
 testing with more cases in the >5g group would be ideal to confirm this trend. 
 
 7.4.2 Macroscopic appearance 
 
 Most of the sputum samples (n=93; 31.2% positive sputum) were noted as 
 macroscopically white mucus.  7 Cases were macroscopically bloody and all of these 
 (100%) had malignancy confirmed on FNA.  5 of these had positive sputum (71.4%).  
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 Statistically, no significant association or trend could be established (p > 0.05), 
 since there are too few cases in the watery, purulent and bloody categories. 
 
7.5 Inter-observer variability 
 
3 of the authors independently, and partially blinded, reviewed the abnormal sputum cases 
identified by manual and automated screening.  These were categorised as stipulated in 5.6. 
No inter-observer agreement was established (0.02 to -0.009 Cohen Kappa).  When 
individual results were compared to the consensus result, at least some agreement was 
obtained varying from 0.45 (fair) to 0.27 (slight).  The low Cohen Kappa values and wide 
confidence intervals which include the point zero, confirm the difficulty of sputum diagnosis, 
poor reproducibility and consensus between cytologists. 
 
7.6 Automation processing performance 
 
The overall performance of the FP on sputum samples was better than expected with 90.0% 
of cases (n=108) qualifying for FOV review.  Expectations were based on the pilot study 
which was retrospective and utilised fairly old cases.  Only 41.7% of those cases qualified 
after automated screening.  Reasons for these poor results were attributed to fact that the 
slides were old resulting in staining deterioration and air bubble formation.   
   
7.6.1   Initial automation success  
 
Initial automation success was achieved in 70.8% of cases (n=85).  This indicates 
that both slides of the sputum were qualified after the first attempt of automated 
screening, and amenable to FOV review.  This is a good result even if compared to 
Pap smear automation, since: 
 2 slides were processed instead of the usual 1 slide for a Pap smear. If only 
one of the slides succeeded, it was removed from this category 
 The FP experienced complications throughout the study period due to a 
defective image system, increasing process review percentage 
 Average automation success for Pap smears during the study period was 
85.3% 
 This instrument was designed for Pap smears and not yet adjusted for sputum 
which may improve results 
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7.6.2 Process review cases 
 
10.8% of cases (n=13) did not qualify for FOV review after initial FP processing.  The 
process review comments included dirty coverslip, poor cellularity or too thick smears.  
Slides were cleaned and reloaded into the FP and subsequently succeeded 
automated screening.   
 
Only 8.3% of the cases (n=10) had to be either reloaded more than once or even re-
prepared.  Most of the process review comments were due to poor cellularity.  These 
cases eventually succeeded automated screening. 
 
7.6.3 Failed automation 
 
10.0% of the cases (n=12) failed automation even after several attempts including re-
preparation.  Sputum volumes were small and most of the process review comments 
were due to poor cellularity.  These 12 cases had to be excluded from the study since 
successful automation was the most important inclusion criteria.   
 
3 of these cases contained abnormal cells and did not qualify for FOV review due to 
“scant cellularity”.  Often positive cases contain numerous malignant cells, but with 
insufficient reference cells according to minimum automation criteria.  When the FP 
rejects these cases they appear on the print set under “qualified slides”, but with 
review. These cases warrant attention and therefore the FP forces cytotechnologists 
to manually screen the case as part of its inbuilt quality assurance.   
 
 7.6.4 Process review status 
 
When slides do not qualify for FOV review, reasons are provided on the print set.  In 
this study, 54% of process reviews’ were attributed to poor cellularity.  This could be 
ascribed to the small volume sputum samples that were obtained (average 1.97g).  
Other reasons included sub-optimal staining (20%), thick smears (14%) and dirty 
coverslips (12%). 
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7.7 Inadequate sputum 
 
Besides the 12 cases that failed automation mainly due to scant cellularity (see 7.6.3), a 
further 16 cases (14.8%) in the study (n=108) had a final sputum diagnosis of “Inadequate” 
due to reasons other than failed automation.  These included absent or too few alveolar 
macrophages (n=12) and more than 75% of cells obscured by an inflammatory exudate 
(n=4). 
 
7.7.1 Inadequate amount of alveolar macrophages 
 
At this laboratory it is practise to count at least 7 carbon-laden macrophages per slide 
to render the sputum adequate. This minimum criterion was adopted from the 
Monograph in Respiratory Cytology published in 1979.(67) Current literature does not 
require an exact number for adequacy, but rather states “an abundance of alveolar 
macrophages should be present.”(64)  The presence of alveolar macrophages 
indicates that the sputum is representative of the lower respiratory system.  When 
only saliva is present, it is considered inadequate.   
 
All the sputum cases (n=12; 100%) with absent or sparse alveolar macrophages had 
negative sputum results, but with subsequent carcinoma confirmed on FNA (i.e. false 
negative results).  These specimens consisted of saliva only. It is therefore 
recommended to ask for an early morning, deeply coughed, repeat sputum. 
 
7.7.2  Cells obscured by inflammation (>75%) 
 
It is important to note that the presence of inflammatory exudate does not exclude 
malignancy.  Patients with bronchogenic carcinoma may have concurrent obstructive 
pneumonia and this may be evident on the slide as an inflammatory background.  
When most epithelial cells are obscured by inflammation, it is recommended to ask 
for repeat sputum after treating the infection.  This will reduce the risk of missing 
abnormal cells obscured by inflammation.   
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7.8 Sputum with inflammatory exudate  
 
Marked inflammatory exudate was noted when > 50% of cells were covered by inflammation 
(predominantly neutrophils).  40.0% of all the patients with confirmed carcinoma, had 
markedly inflammatory sputum (n=36). This could contribute to the low sputum sensitivity.  
Marked inflammatory exudate in the background of scant malignancy may lead to false 
negative results. Diagnostic epithelial cells may be obscured by inflammatory cells or 
cytologists may decide that the sputum merely represents an inflammatory condition and 
screen slides less diligently.  This is a potential and significant diagnostic pitfall for 
cytologists. 
 
17 of the positive sputum (n=35) had marked inflammatory backgrounds, indicating that 
48.6% of these patients’ possibly had concurrent obstructive pneumonia with bronchogenic 
carcinoma.   
 
7.9  Final diagnostic procedure  
 
This section discusses the various methods used to confirm the final diagnoses of the 
patient. Originally this study was designed to use the TBNA/TTNA results as the control or 
gold standard, however occasionally these procedures were abandoned.  Pulmonary FNA 
reported on by an experienced cytopathologist is accurate for subtyping carcinoma and is 
now an acceptable, and at some institutions the preferred diagnostic modality.(22-25)  
Treatment may be planned on these results and molecular analysis can be done, thus not 
requiring more invasive procedures.(26)  
 
FNA of a palpable lymph node or mass, pleural tap or biopsy was intermittently performed in 
this cohort.  These patients were also included in the study.  As expected, TBNA (n=45, 
41.7% of total cohort) and TTNA (n=46, 42.6% of total cohort) were the two most common 
diagnostic procedures used to confirm the final diagnosis.   
 
A significant association between the diagnostic procedure and sputum cytology was 
obtained.  While comparing TBNA and TTNA, there is a significant difference between the 
positive and negative sputum results.  When patients had a TTNA as diagnostic procedure, 
they were more likely to have positive sputum cytology.  
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7.9.1. Transbronchial fine needle aspiration 
 
While TBNA’s are usually the procedure of choice in central tumours, only 28.9% 
(n=11) of sputum was positive in patients with bronchogenic carcinoma.  Previous 
researchers have shown that central lesions exfoliate diagnostic cells more readily in 
sputum, but these results had no significant association (44.0%, p>0.05).(34, 38) 
 
7.9.2. Transthoracic fine needle aspiration  
 
TTNA results were higher than logically expected since this procedure is only 
performed when a peripheral lesion is present.  43.2% of these patients (n=19) had 
positive sputum.  According to literature, peripheral lesions exfoliate cells less 
frequently in sputum.(20, 33, 34, 65)   
 
When patients are amenable to a TTNA, this does not exclude a concurrent central 
tumour as well.  21 patients with bronchogenic carcinoma in this cohort (47.7%) with 
TTNA as the diagnostic procedure also had central lesions recorded.  A tumour 
abutting the chest wall is also a marker of advanced disease.  TTNA is only 
performed for diagnostic purposes, and not for staging purposes as with TBNA.  
 
 7.9.3 Other miscellaneous diagnostic procedures 
 
2 patients had a malignant diagnosis confirmed with bronchial brushings (28.6%).  1 
of these patients had positive sputum. 
 
Bronchial and pleural biopsies were used in 5 patients to confirm the final diagnosis.  
Only 2 patients (40.0%) had carcinoma with no positive sputum. 
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FNA (other than lung) was used in 4 cases to confirm carcinoma: 
 
 1 Patient had various metastatic lesions including chest wall, back and breast 
masses with a positive sputum 
 1 cervical lymph node with a positive sputum  
 1 supraclavicular lymph node with a positive sputum 
 1 metastatic liver lesion with a false negative sputum 
 
Pleural fluid was obtained in 1 patient.  This patient also had positive sputum. 
 
7.10 Final diagnosis of study population  
 
91 patients had a final diagnosis of carcinoma (84.3%), while 17 patients in this cohort had a 
benign diagnosis (15.7%) documented. These benign cases were incorporated as negative 
controls to test the sputum specificity. 
 
7.10.1 Malignant cases 
 
The three most common carcinomas in this cohort were diagnosed as 
adenocarcinoma (n=33; 36.3% of all malignant cases), squamous cell carcinoma 
(n=30; 33.0%) and small cell carcinoma (n=15; 16.5%) using diagnostic procedures 
described in 7.9.  The incidence of adenocarcinoma in this study is not as high as 
described by Nanguzgambo. (55.4%) from the same institution, nevertheless it is still 
the most common primary bronchogenic carcinoma in this cohort.(49) 
 
The other carcinomas diagnosed included large cell undifferentiated carcinoma (n=3; 
3.3%), adenosquamous cell carcinoma (n=2; 2.2%), non-small cell carcinoma NOS 
(n=4; 4.4%), poorly differentiated carcinoma (n=3; 3.3%) and one plasmacytoma 
(n=1; 1.1%). 
 
In 13 cytology specimens and 2 biopsies, immunocytochemistry was requested to 
confirm the diagnosis.  This was most frequently used to confirm neuroendocrine 
origin (n=4), epithelial origin (n=4) and a biphasic nature (n=2).  In effect only 16.5% 
of the malignant cases needed immunocytochemistry.  The diagnosis was based on 
morphology, enabling costs to be kept to a minimum. 
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7.10.2 Resection rate of cohort 
  
At the same institution, Nanguzgambo reported that only 4.4% of lung tumours were 
resectable in a large consecutive series of cases representative of those included in 
the present study.  The reasons for this low rate included the fact that patients 
presented with advanced disease at the time of diagnosis.(49)  With the high burden 
of tuberculosis in the Western Cape (18), patients are often initially treated for 
tuberculosis when they present with a pulmonary lesion or symptoms of pulmonary 
disease.  Patients only return after medication does not clear up symptoms, allowing 
for further tumour progression.  
 
In this cohort, 7 patients (7.7% of patients with bronchogenic carcinoma) were 
possible candidates for surgery, i.e. stage IIIA or less. Of these 7, only 1 patient had 
positive sputum.  Contributing factors used to confirm if patients are candidates for 
surgery includes: general performance status of the patient, patients’ choice to 
undergo surgery and other co-morbidities. These factors were not further investigated 
in this study.    
 
7.10.3 Benign cases 
 
Patients that are referred to the Division of Pulmonology for a diagnostic procedure, 
are suspected of having bronchogenic carcinoma.  This however does not exclude 
the possibility of a benign condition or disease as the final diagnosis.   
 
Mycobacterium tuberculosis (18) was diagnosed and confirmed with culture in 4 
patients (23.5% of all benign cases).  3 patients were diagnosed with granulomatous 
inflammation, but with negative TB cultures (17.6%).   1 patient had acute 
inflammation (5.9%) with Streptococcus pneumoniae confirmed on culture. 
 
In 8 patients no malignancy was found, and a diagnosis of “benign, NOS” was 
rendered (47.1%). Only benign bronchial cells were present on cytology with no 
pathogens identified or marked inflammation.  TB cultures were also negative after 42 
days.  In 1 TBNA, atypical bronchial cells were seen but with extremely scant 
cellularity.  This patient had no follow-up procedure performed. 
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7.11 Sensitivity and specificity of sputum 
 
7.11.1 Sputum sensitivity 
 
Since this study recruited high risk patients, it was anticipated that a fairly high 
sensitivity could be obtained from the sputum.  True positive sputum was established 
in 35 (8=suspicious, 27=malignant) of the 91 patients with bronchogenic carcinoma.  
This equates to a sensitivity of 38.5%.  This result is within those described in the 
literature where the range is very wide.(35) 
 
The low sensitivity of sputum cytology in screening poorly selected populations is the 
reason for its virtual extinction in developed countries.  In South Africa and other 
developing countries, sputum cytology can continue to play a role in the work-up for 
bronchogenic carcinoma.  In decentralised services typically found in such settings, 
patients receive initial medical assessment at their local clinic or hospital and sputum 
cytology can be requested as a first investigation when bronchogenic carcinoma is 
suspected.  Patients then have to travel long distances to receive specialised 
diagnostic procedures and care in poorly resourced tertiary institutions. (83)    
 
7.11.2 Investigation of the false negative rate 
 
This study found a false negative rate of 51.9%.  When these results are further 
categorised, 15 cases (26.8% of the false negative sputum) were deemed 
inadequate. 12 cases had absent or too few alveolar macrophages present and 
consisted predominantly of saliva.  These cases were clearly not well representative 
of the lower respiratory tract, and would have been recommended to repeat.  3 Cases 
had extremely inflammatory exudates present masking more than 75% of the 
epithelial cells and was subsequently not deemed adequate.  These cases were also 
recommended for repeat sputum. 
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When a diagnosis of “atypical, NOS” is rendered, atypical cells are present but the 
potential/significance is uncertain.  12 cases (21.4% of the false negative sputum) 
contained only a few atypical cells and the decision between inflammatory/reactive 
changes and suspicious for malignancy was not possible.  These cases were also 
recommended for repeat sputum. 
   
In conclusion, these 27 (48.2% of the false negative sputum) cases described would 
have been repeated in the clinical setting and the repeat sputum might have revealed 
carcinoma.   
 
The cases of concern are the 29 cases (51.8% of the false negative sputum) that 
were diagnosed as benign and adequate.  These cases were deemed truly false 
negative sputum accounting for 26.9% of the total cohort.  True false negative result 
was reported when manual screening, FP screening and re-screen had a consensus 
benign diagnosis.  From a practical point of view, no clinician will declare a patient 
initially suspected of bronchogenic carcinoma free of such suspicion based on a 
negative sputum cytology result alone and should proceed to more invasive 
investigations.  
 
7.11.3 False negative FP results 
 
2 cases were missed with automated screening (no atypical cells in FOV’s).  These 
included one adenocarcinoma and one small cell carcinoma.  Retrospectively, 
smears showed very sparse atypical cells and in both cases relatively small cells with 
high N/C ratio’s.  One of the cases (adenocarcinoma) only had a single group of cells 
present towards the edge of the coverslip. 
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7.11.4 Sputum specificity 
 
17 benign cases were included as negative controls to test the specificity.  100% 
sputum specificity was achieved since no false positive diagnosis was made.  This is 
an important factor and indicates that a patient with positive sputum needs 
specialised care and urgent follow-up, as patients are very likely to have 
bronchogenic carcinoma. 
 
7.11.5 Sputum sensitivity in histological subtypes  
 
Squamous cell carcinoma showed a significant association with positive sputum 
(n=18, p<0.001) resulting in 60.0% sensitivity. Neumann et al. also reported that 
squamous cell carcinoma was more often identified in sputum compared to the other 
histological subtypes. They obtained an overall sensitivity of 62.3% in a category 
named “pre-malignant or worse” cases, while only 34.8% sensitivity in “positive for 
cancer cells” specimens. 
 
Adenocarcinoma was only present in 10 cases (30.3%).  The results are comparable 
to data from Neumann et al. who reported 36.1% sensitivity in spontaneously 
obtained sputum.(30)   
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Small cell carcinoma had the lowest sensitivity of all the histological subtypes with 
only 2 cases (13.3%) identified on sputum.  This data does not correlate with studies 
in the literature. (8, 11, 30, 53)  Assessment of this low sensitivity recognised that: 
 Malignant cells are usually degenerate in sputum with obscured nuclear detail 
and fragmentation 
 Cells are typically small (1-2x size of lymphocyte) due to poor preservation 
and may be missed 
 Diagnostic cells are usually sparse and may occur singly or in small 
aggregates 
 Cells may resemble lymphocytes and often lack moulding 
 Cells are often dispersed in Saccomanno preparations 
 
7.11.6 Prediction of histological subtype in malignant cases on sputum 
 
Recent advances in conventional and targeted chemotherapy have necessitated that 
cytopathologists refine their diagnosis.  The distinction between squamous cell 
carcinoma and adenocarcinoma is important for predictive, prognostic and treatment 
reasons.(87)  The positive sputum cases in this cohort reported correctly on the 
specific histological subtype in 15 squamous cell carcinomas (83.3%), 4 
adenocarcinomas (40.0%), and 2 small cell carcinomas (100%).   
 
These results are not adequate to commence treatment and indicate that alternative 
diagnostic procedures are essential.  In this institution, as in most of Africa and the 
developing world, specialised chemotherapeutic agents are not available in the public 
health sector and a diagnosis of non-small cell carcinoma is still sufficient.  This is 
unlikely to change in the near future due to the high cost involved with modern 
palliative treatment. 
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7.12 Predictors of positive sputum  
 
6 factors were identified that were significantly associated with positive sputum: 
 Endobronchial tumour 
 Partial airway obstruction / stenosis 
 Round mass 
 Spiculated mass 
 Loss of weight 
 Squamous cell carcinoma 
 
Data from all 6 factors were available in 39 cases of which 9 (23.1%) had positive sputum 
cytology. Receiver operating characteristic (ROC) analysis revealed the best diagnostic 
cut-off was the presence of ≥4 of the parameters that would predict positive sputum with 
a sensitivity of 56% and specificity of 83%.(83) 
 
7.13 Quantity of alveolar macrophages 
 
Results from this study indicate that the number of alveolar macrophages is not as vital in 
sputum sensitivity as hypothesised.  True positive and false negative sputum had most 
samples in the category of “abundance of macrophages”. These results do not correlate with 
Greenberg who noted that sputum adequacy is directly proportional to the number of alveolar 
macrophages. (66)  
 
A significant association could not be established between the quantity of alveolar 
macrophages and an improved sputum cytology result.  This study was unable to confirm 
what is reported in the literature or reasoning due to too few samples collected in this cohort 
for statistical calculations and significance. 
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Disease representation did however improve with sputum adequacy in this cohort.  Results 
indicate that 85.3% of true positive (n=29) and 65.5% of false negative (n=36) sputum 
samples were in the category of “abundance of macrophages”.   
 
This high false negative rate in well represented sputum cannot be explained, and will have 
to be integrated with co-factors.  It must be accepted that not all bronchogenic carcinoma 
patients have cells detectable in sputum.  Risse et al. also showed that the mere presence of 
alveolar macrophages does not accurately predict pathology of the lung. (11)  They found 
that sputum cases with low numbers of alveolar macrophages often have false negative 
results.   
 
This study had 16 cases (29.1%) with low numbers of alveolar macrophages, and 36 cases 
(65.5%) with numerous alveolar macrophages in the false negative group.  All of the cases 
without alveolar macrophages (n=9) had false negative results. 
  
7.14. Limitations and disadvantages of sputum automation 
 
Literature advocates that 3 consecutive, early morning sputum samples should be collected 
to improve the sensitivity and identification of bronchogenic carcinoma.(8)  Unfortunately, it 
was not practical in this study.  One spontaneous sputum sample was collected just before 
the planned, diagnostic procedure.  It was already difficult to coordinate with patients often 
arriving late for their procedure.  This was not optimal, and probably played an enormous role 
in the low sputum sensitivity.  The sample size of this cohort was also too small, hampering 
the statistical calculations and interpretations. 
 
Cytologists knew when they were screening cases from this study, which might have created 
bias.  Although they might have anticipated the presence of malignant cells (since these 
sputum samples were from high risk patients), not all the patients attending the Division of 
Pulmonology for a diagnostic procedure will have bronchogenic carcinoma.  As shown in the 
results, 15.7% of patients did have benign conditions.  Although this was a high risk 
population, false positive diagnosis would have negatively affected the specificity.  With 
100% specificity obtained in this study, it indicated that cytologists did not over diagnose 
these sputum cases. You should always be on high level of alertness, no matter the 
population you are screening or clinical information you are provided with. 
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Furthermore, the principal investigator was involved with manual checking and re-screening 
of cases, FP screening and the final diagnosis or consensus process.  Although she had 
indirect access to results of the various arms, the FNA results was only obtained and 
incorporated once all the sputum cases were concluded. 
 
As shown with the high inter observer variability, the review of sputum samples at the GS 
Review Station could result in misinterpretations of the FOV’s and may lead to false negative 
results.  The FP instruments and service plan options are expensive.  This is however 
already in place at the NHLS labs in South Africa for cervical screening.  Training is also 
necessitated to be able to review cases at the FP (same as for Pap smears).  Training is 
conducted in-house for 2 hours.  Staff is able to start reviewing slides straight away which 
are re-evaluated by the trainer until she deems them competent.  This generally takes 2 
days.  Only qualified cytotechnologists with an internal quality control (IQC) for diagnostic 
missed lesions less than 2% and 2 years post qualification should be allowed to review FP 
screened cases. 
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8.  CONCLUSION 
 
Sputum cytology remains an important part of the screening programme for bronchogenic 
carcinoma in the public health sector of South Africa.  South Africa has countless rural areas, 
patients have transport difficulties and limited access to hospitals with costly bronchoscopy 
units.  In health care settings with limited resources, attempts to improve the quality and 
adequacy of sputum (larger volume with more alveolar macrophages), and to improve 
cytology screening and interpretation should be undertaken.  For these reasons automation 
of sputum screening was investigated to ascertain if cytology sputum sensitivity could be 
improved.  
 
Sputum sensitivity of 38.5% in patients with bronchogenic carcinoma was obtained in this 
cohort, with a specificity of 100%.  This was the first prospective evaluation of a novel 
technology for the analysis of sputum samples.  Benefit from this study was apparent in the 
laboratory where automated screening was shown to be more time efficient than manual 
screening, resulting in 83.1% reduction in the screening time spent per case by a 
cytotechnologist.  This indicated a significantly improved TAT, while decreasing 
cytotechnologist fatigue.  Improved sensitivity was obtained when compared to manual 
screening, but this difference was not statistically significant due to the small sample size, 
providing no significant increased benefit to the patient.  Automated screening identified 
94.3% of the positive sputum cases, while manual screening identified 74.3%.   
 
Although the number of alveolar macrophages is not as vital in sputum sensitivity as 
hypothesised, it continues to play an important role.  All of the cases without alveolar 
macrophages had false negative results.  Results indicate that 85.3% of true positive sputum 
and 65.5% of false negative sputum samples fell in the category “abundance of 
macrophages”.  Disease representation did however improve with sputum adequacy, but 
showed no statistical significant association.   
 
It can therefore be concluded that a better exporated sputum with a larger volume/weight  
and more abundant alveolar macrophages, in combination with automated screening for the 
detection of malignant cells can improve the sputum result and decrease the false negative 
rate of sputum cytology. 
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Sputum with a marked inflammatory response remains a potential and significant diagnostic 
dilemma for cytologists.  48.6% of patients with positive sputum had a marked inflammatory 
exudate, indicating possible concurrent obstructive pneumonia.  This may result in false 
negative results since diagnostic cells may be obscured by inflammatory cells or cytologists 
may misinterpret cellular changes or screen slides less diligently anticipating a benign result.   
   
Adenocarcinoma was the most common bronchogenic carcinoma diagnosed in this cohort 
(36.3% of malignant cases).  Sputum cytology showed significant sensitivity for squamous 
cell carcinoma (60.0% true positive sputum; p<0.001), while small cell carcinoma (13.3% true 
positive sputum) had poor sensitivity.  
 
The only clinical, radiological and bronchoscopic findings significantly associated with 
positive sputum included endobronchial tumour (p=0.045), partial airway obstruction / 
stenosis (p=0.007) and round mass (p=0.039).  Factors with negative association included 
spiculated lesions (p=0.026) and weight loss (p=0.049). 
 
Recommendations from this study include adopting automated sputum screening.  After 
successful automation and FOV review, slides can be re-screened by a senior 
cytotechnologist.  This will save a cytotechnologist from initially screening the sputum 
samples.  The FP can also be employed as a quality control tool for sputum screening.  The 
manufacturer of the FP may however not endorse this idea since developed countries do not 
received large quantities of sputum samples.  In South Africa, however, this will be a useful 
extension to the usage of existing FP systems. 
 
Automated screening is also currently under investigation at this institution on liquid based 
cytology of oral and laryngeal brush specimens as an outcome of this study. 
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Appendix E:   
 
Manufacturer addresses 
 
1.  Shandon MUCOLEXXTM Mucoliquefying Preservative 
Thermo Scientific 
171 Industry Drive 
Pittsburgh 
PA 15275 
USA 
www.thermo.com/shandon 
 
2.  IKA ULTRA-TURRAX® T25: S25N – 18G (Saccomanno homogeniser) 
 Janke & Kunkel GmbH & Co. KG 
 IKA® Laboratory Technology 
 Str. 10 
79219 Staufen 
Germany 
www.ika.com 
 
3.  BD FocalPointtm Slide Profiler 
 Becton, Dickinson and Company 
1 Becton Drive 
 Franklin Lakes 
NJ USA 07417 
www.bd.com 
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Appendix H:   
 
Papanicolaou Staining Method (regressive) 
 
Reagent Duration 
95% Ethanol 10 minutes 
80% Ethanol 30 seconds 
50% Ethanol 30 seconds 
Running Water 30 seconds 
Harris Haematoxylin (Merck) 3 - 5 minutes 
Running Water 30 seconds 
0.5% Hydrochloric Acid 2 seconds 
Running Water 30 seconds 
1.0% Lithium Carbonate 3 minutes 
Running Water 30 seconds 
95% Ethanol 30 seconds 
Orange II (Merck) 3 minutes 
95% Ethanol 30 seconds 
EA 50 (Merck) 3 minutes 30 seconds 
95% Ethanol 30 seconds 
95% Ethanol 30 seconds 
100% Ethanol 30 seconds 
100% Ethanol 30 seconds 
100% Ethanol 30 seconds 
Xylene 30 seconds 
Xylene 30 seconds 
Xylene 30 seconds 
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